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 Abstract 
Positive sense RNA viruses include a diverse group of pathogens that cause a wide array of 
diseases that can range from sub-clinical to lethal.  These viruses infect humans and mammals as 
well as a variety of other hosts.  For their successful replication, viruses interact closely with host 
cells from the binding to the receptor to the exit as complete viral progenies. During the events, 
viruses are dependent on host factors for receptor bindings, genome synthesis, and trafficking of 
viral genome and proteins. Thus there have been major efforts on the studies of understanding 
the virus-host interactions in the field of virology.  In my PhD program, I have studied the host 
factors that regulate the replication of viruses using porcine reproductive and respiratory 
syndrome virus (PRRSV) and hepatitis C virus (HCV).  I found that modulation of either the 
viral receptor or cellular signalling pathways had pronounced effects in the replication of 
PRRSV or HCV respectively. Using PRRSV, I found that the modulation of the level of the 
putative receptor CD163 on cells with cytokines significantly influence virus replication, 
suggesting the importance of cytokine presence in environments to determine the replication and 
pathogenicity of PRRSV via receptor expression in vivo.  With HCV, I found that the 
enhancement of the virus replication occurs through the activation of the epidermal growth factor 
receptor/extracellular signal-regulated kinase pathway by bile acids which are abundant in the 
liver where the virus targets in vivo. Furthermore, I found that the bile acid-mediated signalling 
pathway significantly inhibited the antiviral activities against HCV. These results indicate the 
importance of environmental factors such as bile acids and signalling pathways in the replication 
and pathogenicity of HCV in vivo.    
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Abstract 
Positive sense RNA viruses include a diverse group of pathogens that cause a wide array of 
diseases that can range from sub-clinical to lethal.  These viruses infect humans and mammals as 
well as a variety of other hosts.  For their successful replication, viruses interact closely with host 
cells from the binding to the receptor to the exit as complete viral progenies. During the events, 
viruses are dependent on host factors for receptor bindings, genome synthesis, and trafficking of 
viral genome and proteins. Thus there have been major efforts on the studies of understanding 
the virus-host interactions in the field of virology.  In my PhD program, I have studied the host 
factors that regulate the replication of viruses using porcine reproductive and respiratory 
syndrome virus (PRRSV) and hepatitis C virus (HCV).  I found that modulation of either the 
viral receptor or cellular signalling pathways had pronounced effects in the replication of 
PRRSV or HCV respectively. Using PRRSV, I found that the modulation of the level of the 
putative receptor CD163 on cells with cytokines significantly influence virus replication, 
suggesting the importance of cytokine presence in environments to determine the replication and 
pathogenicity of PRRSV via receptor expression in vivo.  With HCV, I found that the 
enhancement of the virus replication occurs through the activation of the epidermal growth factor 
receptor/extracellular signal-regulated kinase pathway by bile acids which are abundant in the 
liver where the virus targets in vivo. Furthermore, I found that the bile acid-mediated signalling 
pathway significantly inhibited the antiviral activities against HCV. These results indicate the 
importance of environmental factors such as bile acids and signalling pathways in the replication 
and pathogenicity of HCV in vivo.    
    
 
 Table of Contents 
List of Figures ................................................................................................................................ ix 
List of Tables ................................................................................................................................. xi 
Acknowledgements....................................................................................................................... xii 
Dedication .................................................................................................................................... xiii 
CHAPTER 1 - Literature Review and Significance ....................................................................... 1 
PRRSV Virus.............................................................................................................................. 2 
Hepatitis C Virus ........................................................................................................................ 4 
Viral Entry and Uncoating.......................................................................................................... 6 
Viral Receptors ........................................................................................................................... 7 
Methods of Identification........................................................................................................ 8 
Modulation and Disruption of Viral Receptors to Alter Virus Replication............................ 9 
PRRSV Virus Receptor ............................................................................................................ 10 
Hepatitis C Virus Receptor ....................................................................................................... 12 
Overview of CD163.............................................................................................................. 14 
Viral Genome and Replication ................................................................................................. 15 
How RNA Viruses Replicate in Host Cells .......................................................................... 15 
PRRSV Virus Replication..................................................................................................... 16 
Hepatitis C Virus Replication ............................................................................................... 19 
Viral Interactions with the Host Cell ........................................................................................ 23 
The ERK Pathway .................................................................................................................... 24 
Viruses Affected by Alteration of the ERK Pathway ........................................................... 26 
How the ERK Pathway May Play a Role in HCV Replication ............................................ 27 
Model Systems for Study of RNA Viruses............................................................................... 27 
HCV ...................................................................................................................................... 28 
Significance of HCV and PRRSV ............................................................................................ 29 
PRRSV Significance............................................................................................................. 29 
HCV Significance ................................................................................................................. 30 
Control of Viral Outbreaks and Spreading ............................................................................... 31 
 v
Control of Hepatitis C Virus ................................................................................................. 32 
References................................................................................................................................. 37 
CHAPTER 2 - Modulation of CD163 Receptor Expression and Replication of Porcine 
Reproductive and Respiratory Syndrome Virus in Porcine Macrophages ............................ 52 
Abstract..................................................................................................................................... 52 
Introduction............................................................................................................................... 52 
Materials and Methods.............................................................................................................. 54 
Cells and Reagents ................................................................................................................ 55 
Generation of Virus Stocks ................................................................................................... 55 
Generation of LLC-PK Cells Constitutively Expressing CD163 ......................................... 56 
Preparation of PAMs and MDMs Derived From CD14 Positive Cells ................................ 57 
The Expression of CD163 and PRRSV Susceptibility in PAMs or MDMs ......................... 58 
Treatment of anti-CD163 Monoclonal Antibody on PRRSV Infection in PAM.................. 58 
Treatments of MARC-145, PAMs, MDMs or CD14 Positive Monocytes with IL-10, TPA or 
LPS........................................................................................................................................ 59 
Flow Cytometry Analysis for the Expression of CD163 or GFP ......................................... 60 
PRRSV Titration................................................................................................................... 61 
Statistical Analysis................................................................................................................ 61 
Results....................................................................................................................................... 61 
LLC-PK Cells Expressing CD163 Support the Replication of PRRSV ............................... 61 
CD163 Expression Correlates with PRRSV Infectivity in Cells of Monocyte Origin ......... 62 
Anti-Porcine CD163 Antibody Reduced PRRSV Infection in PAMs.................................. 63 
Correlation of CD163 Expression and PRRSV Infectivity................................................... 64 
Modulation of CD163 on MDMs and PRRSV Infectivity ................................................... 65 
Discussion................................................................................................................................. 66 
Acknowledgements................................................................................................................... 72 
References................................................................................................................................. 84 
CHAPTER 3 - Bile Acids Promote HCV Replication Through the EGFR/ERK Pathway in 
Replicon-Harboring Cells...................................................................................................... 89 
Abstract..................................................................................................................................... 89 
Introduction............................................................................................................................... 90 
 vi
Materials and Methods.............................................................................................................. 91 
Cell Lines and Reagents........................................................................................................ 92 
The AP-1 and SRE Promoter Assay. .................................................................................... 92 
Cell Cycle Analysis............................................................................................................... 93 
Treatment of Replicon-Harboring Cells with Bile Acids, Inhibitors of EGFR (AG1478) or 
MEK1/2 (U0126), and IFN-α ............................................................................................... 94 
Detection of HCV RNA and NS5b Protein. ......................................................................... 95 
Detection of Phosphor-EGFR and EGFR. ............................................................................ 95 
Statistical Analysis................................................................................................................ 96 
Results....................................................................................................................................... 96 
Bile Acids Increased HCV Replication in 1A7 cells. ........................................................... 96 
Enhancement of Luciferase Activity Under AP1 or SRE Promoter After Bile Acid 
Treatment in GS4.1 Cells...................................................................................................... 97 
Bile Acids Induce a Prolonged S Phase Period in Replicon-Harboring Cells ...................... 97 
Bile Acid-Mediated Promotion of HCV Replication is Correlated with EGFR Pathway. ... 98 
The Inhibitor of EGFR or ERK Restores the Anti-HCV Action of IFN-α in the Presence of 
Bile Acids.............................................................................................................................. 99 
Discussion of Results.............................................................................................................. 100 
ACKNOWLEDGEMENTS.................................................................................................... 103 
References............................................................................................................................... 118 
CHAPTER 4 - The Limitation of Antiviral Effects Against HCV Due to Bile Acids ............... 121 
Abstract................................................................................................................................... 121 
Introduction............................................................................................................................. 122 
Materials and Methods............................................................................................................ 125 
Cell Lines and Reagents...................................................................................................... 125 
Treatment of Replicon-Harboring Cells with Bile Acids, Antivirals, and IFN-α............... 126 
Detection of HCV RNA and NS5b Protein. ....................................................................... 126 
Statistical Analysis.............................................................................................................. 127 
Results..................................................................................................................................... 127 
Bile Acids Significantly Impaired Mono-Therapy Ttreatments Consisting of Ribavirin, 17-
AAG, and Cyclosporine A. ................................................................................................. 127 
 vii
The Bile Acid Mediated Interference in the Anti-HCV Activity of Each Mono-Therapy Can 
be Partially Mitigated Using Dual Treatments of Ribavirin, 17-AAG, or Cyclosporine A in 
Combination with IFN-α..................................................................................................... 128 
Discussion............................................................................................................................... 129 
ACKNOWLEDGEMENTS.................................................................................................... 134 
References............................................................................................................................... 141 
CHAPTER 5 - Conclusion and Future Directions...................................................................... 145 
Appendix A - Permissions .......................................................................................................... 148 
Virus Research Copyright Permission.................................................................................... 148 
Intervirology Copyright Permission ....................................................................................... 148 
 viii
 List of Figures 
Figure 1-1. The PRRSV Virion. ................................................................................................... 34 
Figure 1-2. The HCV Virion......................................................................................................... 35 
Figure 1-3. The ERK Pathway...................................................................................................... 36 
Figure 2-1. mRNA and Structural Organization of CD163.......................................................... 74 
Figure 2-2. PRRSV Replication in Parental LLC-PK or LLC-PK-CD163 cells.......................... 75 
Figure 2-3. The Expression of CD163 and PRRSV Infectivity in PAMs and Differentiating 
CD14 Positive Monocytes. ................................................................................................... 76 
Figure 2-4. The Effects of Anti-CD163 Antibody on the Infection of PAMs with P129-GFP.... 77 
Figure 2-5. The Effects of TPA, LPS, or IL-10 on PRRSV Infection in MARC-145.................. 78 
Figure 2-6. The Effects of DMSO, TPA, LPS, or IL-10 on PRRSV Replication in PAMs. ........ 79 
Figure 2-7. The Effects of DMSO, TPA, LPS, or IL-10 on PRRSV Replication in Differentiated 
MDMs. .................................................................................................................................. 81 
Figure 2-8. The Effects of DMSO, TPA, LPS, and IL-10 on PRRSV Replication in CD14 
Positive Monocytes. .............................................................................................................. 83 
Figure 3-1.  Enhancement of HCV Replication After Bile Acid Treatment in 1A7 Cells. ........ 106 
Figure 3-2. Enhancement of Luciferase Activity Under AP1 or SRE Promoter Control After Bile 
Acid Treatment in GS4.1 Cells. .......................................................................................... 108 
Figure 3-3 Cell Cycle Analysis of GS4.1 Cells After Treatment with Mock, CDCA, GCDCA, 
and U0126 + CDCA............................................................................................................ 110 
Figure 3-4. The Activation of EGFR by the Treatment with Bile Acids in GS4.1 cells. ........... 112 
Figure 3-5. Inhibitors of EGFR or ERK in Bile Acid-Mediated Promotion of HCV Replication.
............................................................................................................................................. 114 
Figure 3-6. Inhibitors of EGFR or ERK in Anti-HCV Action of IFN in the Presence of CDCA.
............................................................................................................................................. 116 
Figure 4-1 Reduction of the HCV RNA Levels in GS4.1 Replicon-Harboring Cells After 
Treatment with Each Antiviral Compound......................................................................... 135 
Figure 4-2. Enhancement in the Antiviral Activity of IFN-α in the Presence of CDCA when 
Combined with a Second Antiviral..................................................................................... 137 
 ix
Figure 4-3. Western Blot Analysis of Antiviral Compounds in Combination with IFN-α and 
CDCA. ................................................................................................................................ 139 
 x
 List of Tables 
Table 2-1. The Cell Population (%) Expressing CD163 or GFP After Each Treatment and 
Infection with P129-GFP for 18 h in PAMs, CD14 Positive Undifferentiated Monocytes or 
Differentiated MDMs............................................................................................................ 73 
Table 3-1. List of Treatment of Replicon-Harboring Cells with Bile Acids, Inhibitors of EGFR or 
ERK, and IFN Alone or Together in this Study.................................................................. 104 
Table 3-2. Cell Cycle Analysis of 1A7 Cells Incubated with Mock-Medium, CDCA (100 μM) or 
GDCDA (200 μM) for 6, 12, or 24 hr................................................................................. 105 
 xi
 Acknowledgements 
I would like to take the time to thank all the people who made the completion of this work 
possible.  I am grateful to the faculty in the College of Veterinary Medicine that have provided 
guidance along the way.  I would especially like to thank my mentor Dr. Kyeong-Ok Chang for 
his guidance and help throughout this process.   I also extend my thanks to my committee 
members Dr. Chapes, Dr. Oberst, and Dr. Rowland for their thoughts and suggestions throughout 
the years I have been here. 
 
My time spent at Kansas State would not have been the same without the support and advice of 
many of my friends that I have made here.  I would especially like to thank my fellow graduate 
students for their help and guidance, as well as a number of staff including David George, Mike 
Hays, Drew Suddith, and Maureen Kerrigan.  The last several years would not have been 
possible without the support and love of my wife Dr. Karen Patton.  Thank you for being willing 
to live apart for nearly the last two years to give me time to finish my doctorate.  I would also 
like to thank Alison Fedrow, for the constant hours of barbing and light hearted scientific 
discussion.  I am extremely grateful. 
 
Lastly, I would like to thank my family for their support and encouragement throughout this 
process. 
 xii
 Dedication 
I would like to dedicate this dissertation to my wife Dr. Karen Patton.  Without her patience and 
constant support I could not have completed this research. 
 xiii
 CHAPTER 1 - Literature Review and Significance 
RNA viruses are a wide ranging and diverse group of viruses that inhabit many different hosts 
and cause diseases ranging from the non-clinical to deadly (8, 215).  Within the past several 
decades a number of RNA viruses have emerged around the world infecting both human and 
domestic animal populations (86, 102, 158, 199).  Both enveloped and non-enveloped RNA 
viruses have been identified. RNA viruses are classified based upon the composition of their 
RNA genome.  The genomic structure of the RNA virus can be either positive or negative sense 
single stranded ribonucleic acid (RNA) or double stranded RNA.  The RNA genome from a 
positive sense virus is considered to be infectious and can be directly translated by the host 
proteins.  There currently exist a number of RNA viruses that no effective vaccine or antiviral 
treatment has been identified.  Within the last several decades several new RNA viruses have 
emerged onto the world scene.  These new viruses are continuing to cause both extensive 
economic losses as well as the loss of life. 
 
In the early 1990’s a new virus began rapidly spreading through the swine herds of both Europe 
and the United States.  This virus originally identified by names such as blue ear disease and 
mystery swine disease but has more recently been termed the Porcine Reproductive and 
Respiratory Syndrome (PRRS).  The causative agent was identified as a positive sense RNA 
virus that was later determined to be an arterivirus (86, 199).  In 1963 scientists developed a test 
to identify Hepatitis B shortly followed by Hepatitis A tests in 1973 (54, 196).  Unfortunately, 
scientists still had not identified the causatative agent of a new post-transfusion illness that they 
had termed Non-A/Non-B hepatitis.  It was not until the 1980’s researchers finally isolated the 
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causative agent of Non-A and Non-B hepatitis (34).  Hepatitis C Virus (HCV) is now known to 
be a worldwide health concern with around 3% of the worlds population persistently infected (2).  
 
The recent outbreaks of multiple unique viruses highlight the need for a better understanding of 
viral host cell interactions.  A better understanding of these interactions may help to significantly 
improve the development of antiviral treatments and vaccines.  Within the research for this 
dissertation I analyzed the effects of the regulation of several host factor on the replication levels 
of both porcine reproductive and respiratory syndrome virus (PRRSV) and HCV.  We 
demonstrated that modulation of either the viral receptor CD163 or the ERK pathway had 
pronounced effects in the replication of PRRSV or HCV respectively. 
PRRSV Virus 
 
Porcine Reproductive and Respiratory syndrome (PRRS) was originally identified in the 
Netherlands in 1987 and later in the United States in 1990 (86, 199), and has sense been 
identified as an economically important disease in swine costing farmers over 650 million dollars 
a year in the United States alone (136).  Before the identification of the PRRS virus and the 
finalization of the disease name, PRRS, the disease had been identified by several different 
names within both North American and Europe including blue eared pig disease, mystery swine 
disease, and mystery reproductive syndrome. 
 
Currently the PRRS virus is broken into two distinct genotypes.  The first genotype consists of 
the North American strains (Type II), characterized by the reference strain VR2332, and the 
second genotype is comprised of the European strains (Type I), characterized by the Lelystad 
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virus.  Recently a number of Type I like viruses have been identified within the United States 
and have been termed Euro-like strains.  Phylogenetic analysis has determined that there is only 
a 60% nucleotide homology shared between these two clades of viruses and antibodies between 
types I and II are not cross protective  (62, 69, 135, 149).  
 
The current PRRSV vaccines only have a limited efficacy and have been demonstrated to revert 
to virulence.  The current modified live vaccines are not cross protective between the North 
American strains and European strains (140).  In the 1990’s Denmark initiated a vaccination 
program, vaccinating a large population of the swine industry with an attenuated North American 
virus (21).  Unfortunately, a portion of the animals that were vaccinated had the attenuated virus 
revert to virulence (21).  Originally, PRRSV could be isolated from infected animals using 
pulmonary alveolar macrophages (PAMs) (71).  Studies were hampered by the lack of an 
immortal cell line supporting PRRSV replication.  In 1983, a sub clone of MA-104 cells was 
identified in which both the European and North American strains replicated to high titers, this 
sub-clone was identified as MARC-145 (13, 89). 
 
Several putative receptors for PRRSV have been identified on MARC-145 and PAMs including 
sialic acid, sialoadhesion, vimentin, and CD163 (29, 45, 46, 89, 190).  In recent studies Calvert et 
al. demonstrated that cells that support viral replication but that are not permissive to PRRSV 
infection, can be rendered permissive by the stable transfection of CD163.  Further they 
demonstrated that the stable transfection of CD163 was able to generate permissive cell lines 
even in the absence of sialoadhesion (29).  While screening the cDNA library for the PRRSV 
receptor Calvert et al. used a recombinant PRRSV virus that encoded the gene for the green 
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fluorescent protein (GFP) within its genome allowing for the easy identification of infected cells.  
The incorporation of this foreign protein was accomplished using a reverse genetic system, or 
infectious clone. 
 
Genome manipulation of an RNA virus is exceedingly difficult without the use of an infectious 
clone.  Infectious clone have been developed for each of the representative strains of PRRSV, 
VR2332 and Lelystad (91, 117, 214).  These infectious clones allow for the exploration of 
individual viral proteins, the incorporation of separate subgenomic open reading frames for 
foreign proteins, and the deletion of portions of the viral genome for the creation of DIVA 
assays.  The incorporation of foreign tags, similar to the GFP recombinant virus outlined above 
allow for the creation of marked vaccines.  These vaccines allow for the identification of 
vaccinated animals, although they do not permit the differentiation between vaccinated and 
naturally infected animals (29). 
Hepatitis C Virus 
 
Hepatitis C Virus (HCV) was originally known as hepatitis of non A or B origins (34).    HCV is 
currently a worldwide health problem with more than 170 million chronically infected 
individuals worldwide, approximately 3% of the worlds total population (2).  The World Health 
Organization (WHO) estimates that there are an additional 3 to 4 million patients infected 
annually of which only 25% show symptomatic infections (3).  Unfortunately, of those 25%, 60 
to 80% will develop chronic infections.  In up to 20% of these chronically infected patients the 
HCV infection will result in liver cirrhosis (114).  HCV is currently the leading cause of liver 
transplants in the United States accounting for over 2/3rds of the liver transplants (126).  The 
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causative agent was later identified as a positive sense, enveloped RNA virus belonging to the 
Flaviviridae family. Through phylogenetic analysis 6 different genotypes of HCV around the 
world have been identified each consisting of a number of subtypes.  The predominant genotypes 
found within the US are genotype 1 and 2 (3). 
 
Each of the 6 genotypes show different response rates to the current standard treatment for HCV 
infection which consists of a combination therapy of high dose pegylated IFN-α and Ribavirin 
(27, 202, 213).  This therapy has been shown to be highly effective in the genotype 2 and 3 
viruses with upwards of 80% of patients showing a sustained virological response after the 
termination of treatment.  Unfortunately, genotype 1 viruses do not respond as well to the current 
treatment regime with only 40 to 50 percent of patients demonstrating a sustained virological 
response after treatment.  There have been documented cases where a number of patients 
infected with genotype 1 viruses were complete non-responders to treatment (105).   
 
The continued development of treatments for HCV has been hampered with the lack of any 
genotype 1 or 2 tissue culture adapted viruses.  Within the last several years with a representative 
strain of both genotype 1 and 2 viruses being tissue culture adapted and the isolation of these two 
representative strains is a significant breakthrough in the field of HCV research (101, 192, 211, 
212, 218).  Unfortunately, the vast majority of HCV virus strains remain fastidious in tissue 
culture.  Prior to the availability of tissue culture adapted HCV viruses researchers often relied in 
replicon-harboring cells.  Stable cell lines were developed expressing either the non-structural 
proteins or entire genome of HCV.  These cell lines containing an HCV replicon proved 
invaluable to researchers attempting to develop antivirals or further understand the replication 
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cycle of HCV.   One of the major remaining benefits of the HCV replicon-harboring cells over 
the tissue culture adapted viruses, is the fact that they are available in a wide variety of genotypes 
and sub-genotypes allowing the comparison of treatments across HCV strains (10, 102, 184). 
 
Using these replicon-harboring cells researchers have focused on two main directions in the 
development of antivirals against HCV infection.  The first involved the targeted development of 
antivirals towards the individual viral proteins, and the second, targeting the host cell pathways 
and proteins that are used during viral replication.   The development of many of the antivirals 
against HCV has been directed at the NS3-4a and NS5b viral proteins (52, 139).  These proteins 
are responsible for the viral protease and RNA-dependent RNA-polymerase of HCV.  A number 
of candidate antivirals have been identified with several in clinical trials.  Unfortunately, the 
rapid rates of mutation in RNA viruses often lead to the generation of non-susceptible mutants 
that these drugs are no longer effective against (163).  The second group of antivirals being 
developed specifically targets host cell factors that are necessary for viral replication.  Targeting 
these cellular factors partially removes the problem associated with viral targeted antivirals 
although resistant mutants have been isolated.  The main drawback to this approach is the 
targeting of host cellular pathways can cause higher toxicity side effects (64, 79, 104, 152). 
Viral Entry and Uncoating 
 
Many positive sense RNA viruses including both PRRSV and HCV bind to their viral receptor 
being displayed on the cell surface.  They are then trafficked into a clathrin coated pit for 
endocytosis into the host cell.  After endocytosis they are trafficked to the early endosome where 
they begin their uncoating process.  Depending upon the virus they escape the endosomes at 
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different points either early endosome or late endosome.  PRRSV escapes from the early 
endosome, and begins to replicate within the cytoplasm of the host cell (124, 188).  HCV also 
escapes from the early endosome by fusion of its viral membrane to the membrane of the 
endosome releasing the viral core into the cytoplasm (18, 60, 106). 
Viral Receptors 
 
Viral receptors can be as varied and diverse as the viruses themselves.  Currently the overall 
knowledge of the viral genome replication, transcription and packaging far outweighs our 
knowledge of viral receptors, although this field of study is rapidly growing.   Multiple methods 
have been used to identify viral receptors including electron microscopy (EM), enzymatic assays, 
competitive based binding assays, cDNA library screening, and monoclonal antibody libraries.  
The first methods of identifying viral receptors were both slow and tedious.  They relied heavily 
on the use of EM and enzymatic methods for the characterization of each individual receptor.  
Recent advances in both genetic and immunologic fields have improved our ability to identify 
viral receptors. The development of monoclonal antibodies libraries against entire cells, 
transfection techniques, and the ability to express soluble forms of receptors from cloned cellular 
genes has allowed some significant advances in the identification of viral receptors.  Although 
these advances have improved our ability to identify these receptors there are still a number of 
difficulties in deducing the primary receptor and co-receptors (61). 
 
Currently a number of viruses have had their cellular receptors and coreceptors identified 
through the use of multiple techniques.  The Polio receptor was identified after transfection of 
resistant mouse cells with a cDNA library derived from human cells.  A gene called Pvr was 
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identified as a molecule which could make the mouse cells susceptible to Polio infection.  For a 
brief period it was also believed that CD44 played a role as a co-receptor for polio because anti-
CD44 antibodies could block Polio infection.  It was later determined that CD44 is found in the 
same lipid rafts as Pvr and the monoclonal CD44 antibodies that had bound CD44 were 
interfering with the binding of Polio to Pvr within the same lipid rafts (153). 
 
ICAM-1 the rhinovirus receptor was identified through the high throughput screening of 
thousands of antibodies looking for an antibody that could block viral infection.  Blocking of the 
ICAM-1 surface receptor was found to block the infection of cells by the majority of different 
serotypes of rhinovirus.  ICAM-1 is a member of the IgG gene superfamily consisting of 5 IgG 
folds (15).  This molecule has since been shown to be the single molecule responsible for virus 
binding and entry (39). 
Methods of Identification 
 
A number of different methods have been employed to identify viral receptors.    Beginning in 
the 1960’s the binding of purified virions to host cells was observed using electron microscopy.  
Using these images researchers attempted to deduce what receptors played a role in viral entry.  
EM techniques have successfully determined the viral binding sites i.e. polarized cells or specific 
tissue types, but unfortunately, using EM to help deduce the receptors for a virus is often 
problematic due to the low resolution at that scale.  Using EM for receptor identification is 
complicated due for multiple reasons including the low resolution and the inability to 
differentiate between viruses binding to a specific viral receptor and a non-specific interaction 
(61).   
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When determining the viral receptor using enzymatic methods, host cells are treated with varying 
enzymes that are known to cleave specific molecules or families of molecules from the cell 
surface.  After enzymatic cleavage of the surface molecules the cells were subjected infectious 
virus and the resulting infection was monitored.  Populations of cells that are resistant to 
infection suggest putative viral receptors.  Further enzymatic studies are then used to isolate 
individual putative viral receptors.   
 
The process of receptor identification has been further refined in recent years through the use of 
cDNA libraries, monoclonal antibodies, complementation assays, and other techniques.  The 
identification of viral receptors from cDNA libraries relies on a complete cDNA library 
generated from the permissive cell lines (29).  The resulting plasmid library is then either size 
fractionated or otherwise sorted before transfection into a cell line that supports replication but 
not viral entry.  Once a group of plasmids that confers susceptibility is isolated it is further 
fractionated until the appropriate clone is isolated.  This clone can then be further analyzed to 
determine what gene it encodes.  The use of cDNA libraries has allowed for the identification of 
multiple viral receptors including PRRSV and polio.  Polyclonal antibody libraries against whole 
cells have been generated as a means of identifying cellular receptors required for viral infection.  
Similar to the cDNA libraries these polyclonal libraries are fractionated and their ability to block 
viral infection is quantified (127, 198). 
Modulation and Disruption of Viral Receptors to Alter Virus Replication 
 
The modulation or disruption of the viral receptors can reduce or abolishes the ability of that 
virus to enter the host cells to begin replication.  Treatment of cells with small molecule 
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inhibitors, siRNA’s, transfection of dominant negative mutants are all effective ways of reducing 
the overall expressing and/or function of the viral receptor.  Modulating or disrupting the cellular 
receptor for the HCV virus CD81 using siRNA’s have been shown to block HCV infection using 
an HIV-HCV pseudo-type virus (217).   
PRRSV Virus Receptor 
 
There are currently a number of putative PRRSV receptors that are detailed in the literature.  
Beginning in 1998, Duan et al (48), began exploring the cellular surface antigens that induce cell 
susceptibility to the PRRSV virus.  They developed a series of anti-PAM and anti-PBMC 
polyclonal antibodies and determined that the anti-PAM antibodies and not the anti-PBMC 
antibodies could protect PAMs from PRRSV infection.  Two antibodies 41D3 and 41D5 were 
show to bind specifically to PAMs and not other porcine cells, and had the ability to neutralize 
PRRSV infection (48). 
 
This was followed in 2000 when Therrin et al (183) began to characterize the binding factors of 
PRRSV.  It was shown that PRRSV can bind both PAMs, and MARC-145 cells.  It was also 
noted that PRRSV has the ability to bind to porcine peripheral blood monocytes but showed no 
evidence of replication.  Further studies confirmed that the only peripheral blood monocytes and 
macrophages but not leukocytes could bind the virus.  They were able to block the infection of 
PRRSV by preincubation of the cells with either chymotrypsin or pronase E, after 8 hours in 
culture the cells regenerated the ability to support PRRSV infection.  The results suggest that 
PRRSV can interacts with a specific receptor on the surface of some cells but this interaction is 
not enough to lead to a productive infection (183). 
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In 2002 Delputte et al (46) extended this work by further narrowing down the list of possible 
receptors when they identified that heparin could interact with the PRRSV virus and reduce 
infection of PAMs by 88 or 92% overall, depending on the genotype of PRRSV (American or 
European respectively).  When virus was treated with glycosaminoglycans, which are similar to 
heparin, there was no significant impact on the overall levels of viral infection.  Treatment of 
cells with heprinase significantly reduced the overall levels of cells infected with the PRRSV 
virus.  The M-GP5 heterodimer appears to play a role in the attachment of a heparin-like receptor 
on PAMs.  The research conducted by Delputte was the first to narrow down the possible 
PRRSV receptors to a specific group of proteins (46). 
 
Wissink et al (201), identified multiple glycoproteins that they believed were responsible for 
PRRSV infection in PAMs.  Their work centered on a group of four monoclonal antibodies that 
reacted with protein on the surface of PAMs and were known to block PRRSV infection.  These 
antibodies: 1-8D2, 9.4C7, 9.9F2, and 3-3H2 were shown to be specific to PAM surface antigens 
through the use of immunoflorescence and immunoperoxidase monolayer assays.  Using 
radioimmunoprecipitation assays they identified two separate proteins one 150kDa protein and a 
second 220kDa protein that reacted with the monoclonal antibodies.  Glycosidase treatment 
proved that both of these proteins were N-glycoslyated (201). 
 
Further extending the work of Delpuette et al. (49), Vanderheijden and colleges (190) 
immunoprecipitated a 210kDa protein (p210) and after tryptic digestions demonstrated a 56 to 
91% homology with mouse sialoadhesin and human sialoadhesion respectively.   When the 
cDNA for p210 was cloned into PK-15 cells, the PK-15 cells internalized both American and 
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European strains of the virus through glycoprotein mediated uptake.  They suggested that the 
ability of porcine sialoadhesion to mediated endocytosis of PRRSV virus implicates that it is 
involved in the entry process of PRRSV. 
 
Screening of a cDNA library derived from the total RNA of PAMs Calvert et al. (29) identified 
CD163, a 130kDa protein, that was capable of generating permissive cell lines from previously 
non-permissive ones.  The research showed that CD163 from human, monkey, porcine, mouse, 
or canine cells was capable of encoding a functional viral receptor.  They generated a number of 
stable cell lines that were susceptible to PRRSV infection through 80 serial passages (29).  
CD163 may correspond to the 150kDA protein that was originally identified by Duan in 1998 
(48). 
 
Follow up papers by Van Gorp H et al (187) suggest that CD163 and sialoadhesin play a 
cooperative role in the binding and internalization of the PRRSV virus.  They noted that 
monoclonal antibodies to either sialoadhesin or CD163 could reduce PRRSV infection in PAMs 
by up to 75%.  We have also shown the reduction of PRRSV infection levels using CD163 
monoclonal antibodies.  Confocal analysis showed that PRRSV was internalized in the presence 
of sialoadhesion alone, but never successfully uncoated.  Full PRRSV endocytosis and uncoating 
was only observed in the presence of both sialoadhesion and CD163 (187-189). 
Hepatitis C Virus Receptor 
 
There are currently a number of putative receptors for HCV that have been identified.  The 
putative receptor that has become the most accepted and most researched is CD81.  CD81, a 
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25kDa protein, is a member of the tetraspanin family and was the first putative receptor 
identified for HCV.  As the family name suggests CD81 consists of 4 membrane spanning 
domains, these are connected through 2 extra cellular loops.  HCV E2 protein appears to interact 
with the large extra cellular loop which is conserved between the only 2 known hosts of HCV, 
humans and chimpanzees.  The interaction site of E2 and CD81 has been mapped to residues 
163, 186, 188, and 196 of CD81.   Currently the E2 domains that bind to CD81 are being 
debated.  Four different domains are hypothesized as being the binding domains of E2.  The first 
pair involve aa 480-493 and 544-551 and the second involve aa 612-618 and 384-410 in concert 
with 476-480.  Similar to the PRRSV virus receptors detailed above there is some evidence that 
multiple cellular receptors are required for the entry of HCV (11, 70, 72). 
 
In 1999 two groups proposed a second mechanism for the entry of HCV into the host cell.  
Agnello et al. (4)  and Monazahian et al. (125) reported observations that the HCV virus bound 
low density lipoprotein (LDL).  After binding to LDL it was shown that HCV entered the cell 
through endocytosis of the LDL mediated by the LDL-receptor (4, 125). 
 
In 2002 Scarselli et al (165), proposed a third receptor and mechanism of entry for HCV that 
may play a role in the tissue-tropism of the virus.  Dendritic cell-specific intercellular adhesion 
molecule-3-grabbing nonintegrin (CD209) is expressed to high levels on endothelial cells of the 
liver and has been shown to induce the rapid internalization of HCV pseudo-particles after 
binding.  It is currently thought that the binding of HCV to CD209 is mediated through the E2 
protein similar to CD81.  Further work by Lozach et. al. (103) could not reproduce the results 
showing the rapid internalization of the HCV sudo-particles after binding. 
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 The current model for HCV infection has been significantly modified since the identification of a 
tissue culture adapted virus.  HCV entry is now believed to be a multistep process involving four 
different viral receptors.  The virion initially attaches to heparin sulfate along with the low-
density lipoprotein receptor.  Following this initial interaction the virus binds CD81 and SR-B1 
which triggers the viral uptake via Claudin-1 and occludin (25). 
Overview of CD163 
 
CD163, originally termed M130 and RM3/1, was identified in 1987 as a molecule that was 
capable of producing an anti-inflammatory response (92, 220).  It is a 130-kDa protein that 
consists of 9 scavenger rich-cystine rich (SRCR) domains, a transmembrane element, and a short 
cytoplasmic tail.  There have been multiple splice variants of the protein identified in various 
species including both human and porcine (73, 74).  CD163 has since been defined as a member 
of the scavenger rich-cystine rich superfamily due to its structural and organizational 
characteristics.   The expression of CD163 is restricted to cells of the monocyte-macrophage 
lineage. 
 
Originally, when researchers were looking for the functional role of CD163, it was believed to 
take part in either phagocytosis or the local immune regulation.    To further elicit information 
about these proposed roles of CD163 the monoclonal antibody EDHU1-Ab was used to 
preincubate cells before phagocytosis experiments were conducted.  No difference in the 
phagocytosis of either S. aureus or E. coli were observed after preincubation with EDHU1-Ab.  
While a complete understanding of the cellular functions has not been reached, it is now believed 
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to play a role in haptaglobin/hemoglobin scavenging (53).  This receptor is upregulated in the 
presence of anti-inflammatory cytokines such as IL-10 and the soluble version of CD163 is 
believed to play a role in the anti-inflammatory response (156).  Currently PRRSV and African 
Swine Fever Virus (ASFV) are the only viruses that have been identified using CD163 as a viral 
receptor (29, 162). 
 
It has been demonstrated that it is possible to modulate the overall expression levels of CD163 
on the cell surface of macrophages by treatment with a number of different molecules including 
12-O-tetradecanoylphorbol-13-acetate (TPA), IL-10, and lipopolysaccharide (LPS).  
Macrophages and monocytes respond differently to these stimuli.   CD163 expression on 
monocytes undergoing differentiation can be modulated.  For example the combined treatment of 
monocytes with IL-10 and GM-CSF increased CD163 expression (186).  While the treatment of 
monocytes with GM-CSF and TPA or LPS decreased expression of CD163.  In contrast 
treatment of macrophages with IL-10 leads to no significant upregulation, while TPA caused a 
marked decrease in CD163 levels (26, 186). 
Viral Genome and Replication 
How RNA Viruses Replicate in Host Cells 
 
The positive sense genome alone is all the viral material that is required to start the viral 
replication cycle.  Once the virus has entered the cell, escaped from the early endosome, and 
fully uncoated.  The hosts ribosomes can directly recognize the single stranded positive sense 
RNA as an mRNA.  The positive sense RNA is either translated into one large polyprotein or 
multiple smaller proteins that are encoded within the viral genome (75, 179).  The genome of 
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both HCV and PRRSV encode one or two large initial polyproteins respectively (120, 211).  For 
PRRSV these polyproteins encode all of the nonstructural proteins including the RdRp and 
proteases that are needed to generate the subgenomic mRNAs and replicate the viral genome.  
The required proteases are encoded within the initial polyprotein.  These proteases are involved 
in the initial cleavge of the large poly protein into all the constituent proteins.  A hallmark of the 
Arteriviridae family is the incorporation of a series of subgenomic RNA’s that each encode a 
different structural protein (20, 128, 164).  For HCV this one large polyprotein includes both the 
structural and nonstructural proteins that are needed for further viral replication (50, 101, 157, 
210). 
PRRSV Virus Replication 
 
The PRRS virus is a member of the Arteriviridae family, which along with the Coronaviridae 
and Roniviridae families comprises the genus Nidovirales.  PRRSV is a single stranded positive 
sense RNA virus with a genome size of approximately 15 kb, the exact size is strain dependent 
(38).  The viral genome encodes 8 open reading frames (ORF) which encode at least 22 viral 
proteins (Figure 1-1B).   
 
The PRRSV glycoproteins GP2a, GP2b, GP4, and GP5 are all actively involved in the binding of 
the PRRS virion to the target host cell.  GP2 encodes two open reading frames GP2a and GP2b 
(175).  GP2a contains two distinctive hydrophobic peaks in both the European and North 
American Strains of PRRSV supporting two separate N-linked glycosylation sites (115, 121, 
122, 129).  The small ORF2 protein has been repeatedly demonstrated to associate with 
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intracellular membranes both during active PRRSV replication and after over expression of 
GP2b (Figure 1-1A) (121). 
 
GP4 is a minor membrane glycoprotein that has been associated with neutralizing antibodies 
after Lelystad infection, however these neutralizing epitopes located in the amino terminal amino 
acids 40-79 are not conserved within the North American strains of PRRSV (119, 197).  GP4 has 
a mass ranging from 20 to 35 kDa depending on the level of additional N-glycans that are 
obtained during the transport through the ER and Golgi (119).  GP4 is an immunogenic protein 
with approximately 65% of PRRSV-positive sera from swine farms within the US and Canada 
reacting to recombinant GP4.  GP4 contains multiple hydrophobic sequences at both ends of the 
protein as well as four N-linked glycosylation sites that are conserved across all strains (111, 
115, 122, 123).  It has been suggested that GP4 is involved with the binding of CD163 and 
internalization of the virion into the cell. 
 
ORF5 encodes GP5, the major envelope glycoprotein in the PRRS virion, with an estimated 
weight between 24.5 and 26 kDa (110, 111, 122).  There is an N-terminal signal sequence and 
multiple glycosylation sites.  There is significant genetic variation within GP5 between the 
Lelystad like viruses and their North American counterparts, but the hydropathy profiles remain 
similar (111, 115, 130).  The GP5 protein from both the North American and European strains 
has been shown to have an apoptotic effect in both monkey kidney cells and PAMs (180, 181).  
The over expression of the anti-apoptotic protein BCL-2 did not prevent the GP5 induced 
apoptosis of these cells (180).  The GP5 protein is know to form a heterodimer with the PRRSV 
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M protein creating the primary receptor binding complex (110, 190).  Antibodies to GP5 can 
neutralize PRRSV (197). 
 
The M protein is encoded for by ORF6 and has an estimated mass between 18 to 19 kDa.  It 
possesses three hydrophobic regions assumed to be membrane spanning domains similar to the 
coronavirus M protein and is non-glycosylated (111, 123).    The M protein forms disulfide 
linked heterodimers with GP5 in the ER before further transport of these protein occurs, absence 
of these disulfide bonds prevents translocation to the golgi (110).  The M protein is believed to 
play a role in viral assembly and budding (110). 
 
The nucleocapsid (N) protein is 123 AA, NA strain, or 128 AA, European Strain, in size with a 
molecular weight between 14 and 15 kDa.  It is a highly basic protein that accounts for between 
20 and 40 percent of the total protein in the PRRS virion (12, 109, 111, 122, 134).  The N protein 
is present primarily as a homodimer and multimerizes to form the icosahedral core protein of the 
PRRS virus (110, 122).  There are multiple conserved immunogenic epitopes between the North 
American and European strains of this virus (42, 47, 118, 134). 
 
The GP5 and M heterodimer comprise the main membrane proteins of the PRRSV virus which 
are responsible for the initial binding of the virion to the host cell (43, 82, 205).  Recent research 
suggest that GP5 and M heterodimer bind sialoadhesion on the cell surface and then enters the 
target cell via clathrin-mediated endocytosis facilitated by the interaction of the viral GP2a and 
GP4 with CD163 (41, 187-189).  The PRRS virus then moves into the cell via the early 
endosome where the viral RNA is released into the cell (188).  After uncoating in the early 
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endosome and the release of viral RNA into the target cell ORF 1a and 1ab are initially 
translated (Figure 1-1C).  The two initial polyproteins are further cleaved by a series of four 
different proteases including papin-like cysteine proteases PCPα and β located within Nsp1, a 
cysteine like protease located within Nsp2, and the main serine protease 3CL Pro that is located 
within Nsp4 (5, 7, 19, 176, 219).   
 
The second step is the transcription of negative sense and subgenomic RNA fragments.  After the 
expression and cleavage of these non-structural proteins, these proteins interact with the viral 
genome transcribing the minus-strand subgenomic RNA’s and full genomic template from the 3’ 
towards the 5’ end of the viral genome (116).  ORF’s 2 through 7 encode all of the structural 
proteins including: GP2a, GP2b, GP3, GP4, E, M, and N.  These proteins are expressed from a 
nested set of subgenomic RNA’s (43, 117, 120, 203, 204).  Each separate subgenomic ORF is 
preceded by a short leader sequence that is recognized by the 5’ leader sequence.  The synthesis 
of the minus-strand is discontinuous and yields a series of minus-strand subgenomic RNA’s that 
are used as template for the generation of plus-strand subgenomic RNA’s (20, 128, 133, 144).  
The positive sense subgenomic RNA’s are then translated into the proteins corresponding to 
ORFs 2-7 (164).      
Hepatitis C Virus Replication 
 
The HCV viruses are divided into 6 genotypes and multiple subtypes and are a member of the 
Hepacivirus genus and Flaviviridae family (50, 83, 85, 101).  Similar to other members of the 
Flaviviridae family it is surrounded by a lipid bilayer that is anchored by multiple envelope 
proteins (Figure 1-2A).  This envelope envelopes the nucleocapsid core that is composed of the 
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HCV RNA genome and the core protein.  The HCV virus is composed of a positive sense single 
stranded RNA genome that encodes a single large polyprotein.  The gnome is 9.6kBp encoding 
over 3000 amino acids (Figure 1-2B) (1).  The polyprotein encodes at least 10 distinct proteins 
and is cleaved by the NS3-4a protein (16, 40, 112).   The majority of the structural proteins are 
encoded on the 3’ end of the viral genome.  The main open reading frame within HCV is flanked 
on either side by both a 5’ and 3’ untranslated region. 
 
The length of the untranslated regions within this family of viruses is variable ranging from 95-
555 bp for the 5’ UTR and 114-624 bp for the 3’UTR.  The 5’ UTR of HCV contains 341 nt 
prior to the beginning of the main ORF (22, 30, 68, 76, 170, 177).  Within this ORF there are 4 
conserved regions corresponding to 4 separate highly structured domains.  The domains 2 
through 4 and the 5’ most portion of the HCV core protein form the HCV internal ribosome 
binding site which is capable of directly binding the 40s ribosomal subunit (138, 185, 193, 194).  
Similar to the 5’ UTR the 3’ UTR contains multiple stem loop structures and is divided into three 
distinct regions.  The first region consists of a 30-40 nt variable region directly followed by a 
poly(U)-poly(UC) stretch.  The final region is a highly conserved stretch encoding 3 stem-loop 
structures termed SL1, SL2, and SL3 (68).  The 3’ UTR has also been shown to interact with the 
HCV RdRp, NS5b, through multiple stem loop structures (55).  Any disruption in the 52 nt 
upstream of the poly(U) tract or the multiple stem loops results in the disruption of RNA 
replication 
 
The HCV virion is comprised of 3 main structural proteins the two envelope proteins and the 
core protein.  The E1 and E2 proteins are responsible for the initial binding of the HCV virion to 
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CD81 and are essential for the viral life cycle.  These two proteins are responsible for numerous 
other viral functions including membrane anchoring, ER localization, and heterodimer assembly 
(141).  Both the E1 and E2 proteins are transmembrane glycoproteins that contain 5 or 11 
glycosylation sites respectively (51).  The E2 protein contains a region often termed hyper-
variable region one.  This region can differ in sequence homology by up to 80% depending on 
the genotype of HCV virus (191).  Although there is high nucleotide variability in this region the 
overall protein structure, and biochemical properties of each of the amino acids remain constant 
suggesting this region is crucial to the viral lifecycle (146).  This hyper-variable region consists 
of 27aa and is a major neutralizing epitope (148). 
  
At the center of the HCV virion is the core protein which comprises the other structural protein 
encoded for in the HCV genome.  This protein is a highly basic protein that has been shown to 
bind RNA and is thought to play a major role in the formation of the HCV capsid.  Upon original 
processing the core protein is 191 aa and approximately 23kDa.  The final form of this protein 
appears to be predominantly 21kDa although sizes ranging from 17 to 23 kDa have been 
detected (171).  This protein consists of three separate domains consisting of and N-terminal 
hydrophilic region, a C-terminal hydrophobic region and a short signal peptide located on the 3’ 
end of the protein (84, 147).  The positive charges found within the N-terminal domain are often 
characteristic of the RNA binding portion of a protein and also contains multiple nuclear 
localization sequences (80).  The core protein has also been shown to have several ties to the 
viral life cycle including interaction with cellular proteins and both pro and anti-apoptotic 
properties (31, 100, 137, 209). 
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After the initial binding of the virion and internalization via claudin-1 and occluding into the 
early endosome the membrane of the HCV virion fuses with the endosome.  This fusion allows 
the viral core to escape into the hosts cytoplasm where the 40s subunit directly binds to the IRES 
within the HCV genome.  After the binding of the ribosome to the IRES one large polyproteins is 
initially produced.  The NS3-4a protease plays a crucial role in the proteolytic cleavage of the 
large HCV polyprotein.  Multiple groups have determined the structure of the NS3-4a protein 
and the catalytic triad has been localized to His 57, Asp 81, and Ser 139 (67).  NS3 alone also 
contains a domain termed the NS3 helicase-NTpase domain.  Multiple functions of this domain 
have been identified including RNA-stimulated NTPase activity, RNA binding, and unwinding 
of secondary and tertiary structures of RNA.  Levin et al (94) suggested that the NS3 helicase 
translocates along the RNA (94).  Recently other functions of the NS3-4a complex have recently 
been elucidated.  This complex has been implicated in the regulation of the innate immune 
system during viral infection. In 2003 the NS3-4a protein was shown to antagonize the dsRNA-
dependent interferon regulatory factor 3 (IRF-3).  IRF-3 is a critical player in the modulation of 
the interferon induction in response to viral infection (63, 96).  This does not appear to be the 
only location in this pathway that NS3-4a disrupts.  Further studies in 2005 suggest that NS3-4a 
blocks the signaling of dsRNA through the TLR-3 receptor (97).  In addition to the disruption of 
the IFN system in response to viral infection the viral protease is also responsible for the 
cleavage of the large precursor polyprotein (Figure 1-2C).   
 
The other nonstructural proteins that participate in the formation of the replication complex and 
modulation of various cellular pathways include NS4b, NS5a, and NS5B.  NS4b appears to 
function as a membrane anchor for the HCV replication complex.  Structural predictions indicate 
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that there may be up to four distinct transmembrane domains included within this 241 aa protein 
which may play a role in the ER membrane localization (98). 
 
NS5a is crucial for HCV replication and is found in association with lipid rafts (113).  It has been 
implicated in the modulation of various cellular pathways and known to interact with the vesicle-
associated membrane-associated protein.  There is currently evidence that NS5a 
hyperphosphorylation can cause the negative regulation of HCV RNA synthesis by disruption of 
hVAP-33 (65).  Further reports suggest that NS5A hyperphosphorylation is crucial in the virus 
lifecycle because it acts as the trigger that pushes the virus from a replication stage into an 
assembly stage (78).  Direct interaction between NS5A and NS5B have been observed but the 
actual effects of this interaction are currently unknown (99). 
 
NS5B is the RNA-dependent RNA-polymerase encoded within the virus (14).  NS5B has 
recently been reported to bind to cyclophillin B which appears to regulate HCV replication 
(195).  NS5B has been reported to be a tail-anchored protein with the terminal 21 residues 
anchoring to the ER exposing the proteins functional domain (167).  Structural analysis of NS5B 
has shown that it has a classic RdRp structure (108).  Each of these structural and nonstructural 
proteins plays a crucial role in the replication of the HCV genome, alteration of cellular 
pathways, and blocking of innate immune responses. 
Viral Interactions with the Host Cell 
 
All viruses require a number of cellular factors for their replication.  This reliance on these 
various host factors has directly tied the replication cycle of many viruses to specific pathways 
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within their host cells.  Disruption of these individual pathways is known to reduce the viral 
replication levels.  Viruses such as Dengue and West Nile Virus have demonstrated the ability to 
modulate their respective host cell cycles.  Synchronization of the cell cycle to a stage other than 
that required by the virus greatly reduces the overall viral levels (33).  Measles virus induces a 
cell cycle hold at G0, which is believed to play a role in the virus’s immunosuppressive abilities 
(132). 
 
Multiple viruses including influenza, PRRSV, vaccinia virus, and HCV have developed ways to 
disrupt the innate immune response in their host cells.  Influenza’s NS1 can bind dsRNA and 
sequester retinoic acid-inducible gene 1 (RIG-1) preventing the downstream activation of 
interferon response factor-3 (IRF-3).  The PRRSV NS1 protein has recently been shown to 
attenuate IRF-3 and NF-kappaB-dependent gene induction by dsRNA (17).  Vaccinia virus 
encodes over 200 individual genes, over half of which are not necessary for viral replication in 
cell culture.  The majority of these genes encode proteins that are responsible for the modulation 
of various host cell pathways, the innate immune response, or have some function in the host 
infection cycle. 
The ERK Pathway 
  
The ERK pathway is stimulated by multiple factors including growth factors and bile acids.  The 
binding of one of these stimulants to the cell surface receptor EGFR initiates signaling through a 
series of tyrosine kinases.  EGFR contains 9 separate phosphorylation sites, 8 of which are 
autophosphorylated (95).  These phosphorylated sites function as the binding site for the Shc 
homology 2 and phosphotyrosine binding domains of multiple adapter proteins (166).  After the 
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binding of growth factor to EGFR the signaling pathway requires the presence of Shc, Grb2, and 
SOS to initiate the phosphorylation of RAS.  RAS is a member of the GTPase family of proteins 
that hydrolyze GTP and was first identified as a transforming oncogene of the murine sarcoma 
viruses.  Viruses have been shown to encode three separate forms of RAS Harvey-Ras (H-Ras), 
Kirsten-Ras (K-Ras), and Neuroblastoma-Ras (N-Ras) (173).  These Ras variants all lack the 
ability to hydrolyze GTP and are constitutively active.  Ras activates the next step in the pathway 
Raf. 
 
Raf was originally discovered as a viral encoded transforming agent v-raf (154).   Raf is a 
member of the MAP3K family and is classified as a Ser/Thr kinase.  Ser/Thr kinases catalyze the 
phosphorylation of both Ser and Thr residues.  Mammals are known to express 3 different forms 
of Raf ranging in size from 70 to 100 kDa (93).  To fully activate Raf 4 separate phosphorylation 
sites must be phosphorylated by Ras.  Of the multiple isoforms of Ras that have been identified 
they all activate Raf with varying efficiencies (32).  V-Ras has the highest activation efficiency 
of Raf that has been identified.  After the activation of Raf, Raf further activates MEK (208). 
 
MEK 1 and MEK 2 are alternatively known as MKK1 and MKK2.  Raf activates MEK by the 
phosphorylation of multiple serine residues located at positions 217 and 221 (6).  Unlike Raf 
MEK is found at high levels within the cells.  This allows for the rapid amplification of the 
signaling pathway after the initial activation events (77).  No viral encoded mutants of MEK 
have ever been identified, although when MEK is constitutively activated it has been shown to 
be tumorgenic (107). 
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ERK is the heart of the pathway that leads to the activation of a number of downstream events.  
ERK1 and 2 are expressed in all examined mammalian tissues with ERK2 being expressed to 
slightly higher levels (142).  For ERK to be fully activated it requires the phosphorylation of 
both Thr202 and Tyr204 for ERK1 and similarly Thr185 and Tyr187 for ERK2 (56).  For total 
control over the ERK pathway there are 9 known dual specificity phosphotases that can 
terminate ERK activation.  The ERK pathway is a critical regulator of the expression of multiple 
genes associated with cell cycle regulation.  The activated form of ERK is responsible for the 
regulation of growth factor-response targets located in the cytosol.  As well as the activation of 
these growth factor-response targets it also translocates to the nucleus where it controls the 
phosphorylation of multiple transcription factors that regulate gene expression (24). 
 
Viruses Affected by Alteration of the ERK Pathway 
 
The replication of multiple viruses has been tied to the ERK pathway.  Herpes Simplex virus 
type 2 has been shown to cause a sustained activation of ERK1/2.  When MEK1/2 are knocked 
down using siRNA or MEK activation is attenuated by treatment with U0126 the replication of 
Herpes Simplex virus type 2 is greatly reduced (216).  Kaposi's sarcoma-associated herpes virus 
(KSHV) has also been shown to activate both MEK and ERK during the course of infection.  
When the host cells were treated with U0126 viral DNA internalization was still observed but 
nuclear delivery of KSHV DNA was significantly attenuated.  Analysis of gene expression after 
treatment with U0126 showed the expression of multiple genes was severely attenuated and only 
a limited viral infection was observed (172).  During reovirus infection the viral oncogene CUG2 
enhances viral replication through the activation of both Ras and p38 signaling (143).  Hepatitis 
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B virus controls the regulation of the c-met promoter through the activation of ERK and 
treatment of HepG2 cells with U0126 can significantly attenuate viral replication levels (206).  A 
number of paramyxoviruses also alter the expression and activation of both ERK1/2.  Inhibition 
of the ERK pathway with U0126 completely eliminates expression of viral proteins after 
infection (28).  Bovine viral diarrhea virus (BVDV) infection in MDBK cells results in the 
increased activation of ERK1/2.  It was shown that BVDV affects the ERK signaling though 
oxidative stress (207).  These data show that multiple viruses have the ability to alter the 
activation levels of the ERK pathway and that attenuation of this activation can significantly 
reduce the overall course of viral infection. 
 
How the ERK Pathway May Play a Role in HCV Replication 
 
HCV protein NS5A alters the trafficking of EGFR and the activation of the ERK pathway.  
Attenuation of signaling through the ERK pathway has recently been demonstrated to reduce the 
overall levels of HCV RNA.  Scholtes et al. also demonstrated that the treatment of HUH7 cells 
with a MEK1 inhibitor U0126 can prevent the replication of HCV after infections (168).  Further 
studies have identified that the enhancement of the ERK pathway can enhance the overall levels 
of HCV replication (23).  It is currently unknown why HCV depresses the activation of the ERK 
pathway but it has been suggested that NS5A may play a role in the creation of a persistent HCV 
infection (155). 
 
Model Systems for Study of RNA Viruses 
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When PRRSV was originally identified it was only able to be cultured on porcine alveolar 
macrophages (PAMs).  Work to find a separate suitable immortal cell line lead to the 
identification of MARC-145 a sub clone of MA-104 cells (87).  Infection of confluent 
monolayer’s of MA-104 cells showed limited infection of the PRRSV virus with no significant 
viral production.  This suggested that a subpopulation of these cells were capable of supporting 
replication of the PRRSV.  The original MA-104 stock subcloned to identify a more permissive 
MA-104 clone, this clone was termed MARC-145.  MARC-145 cells show a high susceptibility 
to the PRRSV virus with titers often reaching 10^7 log TCID50 (88). 
HCV 
 
The genome of HCV was first cloned in 1989, but until recently there had been limited success 
in isolating a HCV virus that could be successfully tissue culture adapted (34).  This lack of any 
tissue culture adapted viruses created the need for a secondary system for the study of the HCV 
virus.  The 5’ end of the viral genome consists of a non-translated region (NTR) that acts an 
internal ribosomal entry site (IRES) (182).  The genome for the first replicon-harboring cells was 
isolated from an infected human liver and recovered using long distance RT-PCR.  A T7 
polymerase promoter and an engineered restriction site on the 3’ end of the clone allowed for the 
efficient production of RNA transcripts.  When transfected these initial RNA transcripts showed 
no evidence of replication in any of the cell lines they were tested in.  To solve this problem 
constructs were generated encoding G418 to enable the selection of cells supporting HCV 
replication.  The HCV RNA within these cells replicated to high titers and expressed all of the 
encoded viral genes (102).  The genomic organization of the current group of replicon-harboring 
cells is slightly modified from the wild type genome.  The 5’ NTR directs the translation of the 
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neomycin phosphotransferase gene.  This is followed by the IRES of the Encephalomyocarditis 
virus (EMCV) which directs the translation of the encoded HCV regions (90).  There currently 
exist replicon-harboring cells from the majority of HCV genotypes.  Replicon-harboring cells 
possess a number of advantages when testing the effectiveness of various antiviral compounds.  
They allow for the rapid screening of multiple compounds across a broad array of HCV 
genotypes.  The effectiveness can be rapidly quantified using qRT-PCR and supplemented with 
western blot analysis. The first HCV virus to be tissue culture adapted was the genotype 2 JFH 
strain (101).  This was followed by the isolation of a genotype 1 virus by Yi et al. (212) in 2006 
that allowed for the recovery of infectious virus particles.  These are the first viral systems that 
allow for the analysis study of a productive HCV infection in vivo. 
Significance of HCV and PRRSV 
PRRSV Significance 
 
The PRRS virus causes significant damage throughout all phases of swine production.  In adult 
swine infection with the PRRS virus causes reduced appetite, fever, premature farrowing and 
abortions, death in up to 10% of sows, and in extreme cases neurological symptoms.  When 
pregnant sows are acutely infected with PRRSV the affected litters can be inflicted with a 
number of different problems, ranging from still born pigs, high pre-weaning mortality, 
mummified pigs, variable sized weak pigs, and adema around the eyes.  Within the group of 
weaned pigs infection results in loss of appetite, lethargy, failure to thrive, labored and rapid 
breathing, blotchy or reddening skin, and a distinctly rough hair coat.  This virus has been shown 
to cause persistent infection in animals and has been detected in boar semen at greater than 200 
days post infection (35, 36, 174). 
 29
 The wide range of problems associated with the PRRS virus costs the US swine industry an 
estimated 600 to 700 million dollars a year causing a significant impact on the overall economic 
stability of the swine industry (136).  Due to the lack of an effective vaccine many of the 
protocols involved in the elimination of PRRSV from production barns can involve a costly 
depopulation/repopulation strategy. These strategies often involve the barn sitting empty for a 
significant period of time to ensure that all virus has been eliminated from the barn.  There have 
been some successful attempts at the eradication of PRRSV from specific areas.  Following 
detailed biosecurity protocols helps to prevent the spread of PRRSV but there is current research 
suggesting that PRRSV can be transmitted limited distances through aerosol (44).  
 
Viral spread throughout a swine barn can take place within a period as short as 7-10 days.  This 
rapid spread can make it difficult to control an outbreak due to the fact that by the time the 
symptoms are noted in the originally infected animals a large portion of the barn is potentially 
infected.   
HCV Significance 
 
HCV is a global health problem with the virus chronically infecting over 170 million people 
worldwide.   The estimated cost of treatment for the 4.5 million infected patients in the United 
States that develop chronic liver disease as a result of HCV infection is expected to reach 360 
billion dollars.  The average lifetime treatment for an HCV patient who does not develop chronic 
liver disease is $100.000 dollars over their lifetime.  Nearly 1,000 patients a year receive liver 
transplants yearly due to the effects of HCV infection.  In the current economy a liver transplant 
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costs approximately $280,000 dollars.  This amounts to nearly 300 million dollars a year alone in 
financial losses.  The net result is a major financial impact in the United States alone, these 
number do not estimate any of the medical costs from other nations (9, 81, 178). 
Control of Viral Outbreaks and Spreading 
 
Many different approaches have been taken to control the spread of virus’s including vaccination 
and the use of antiviral drugs.  Unfortunately there exist a number of RNA viruses that are 
currently no vaccinations for and our current antiviral therapies either are not effective or are a 
long and drawn out sometimes painful process.  Viruses have adapted a number of effective 
strategies for evading the host immune system.  Viral adaptations vary dependent on the virus, 
some viruses have adapted mechanisms create persistent infections hiding from the hosts 
immune system, and others posses the ability completely overwhelm both the innate and 
adaptive immune system of their host.  Several viral infections are actually enhanced by out 
immune system through a form of antibody mediated enhancement. 
 
Within the replication cycle of each virus there are several different points of attack when trying 
to control the replication of these pathogens.  These begin with the viral receptor and the initial 
entry into the host cell, followed by uncoating, replication, assembly, and finally maturation and 
release.  Often times many cellular pathways play an active role in the replication of these 
viruses and also offer an attractive target for antiviral development.  In this series of studies we 
modulated the expression level of the PRRS viral receptor CD163, and explored the interactions 
between HCV replication, the ERK pathway, bile acids, and multiples small molecule antiviral 
compounds. 
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Control of Hepatitis C Virus 
 
HCV is commonly spread through a variety of means including blood transfusions, reuse of 
needles, and sexual intercourse.  The control of HCV within a population begins with education.  
Many routes of HCV transmission can be easily controlled including the use of protective 
measures during sexual intercourse, always using disposable needles, and the screening of all 
blood meant for transfusion purposes. 
 
The current method of treatment using long acting pegylated interferon-α and ribavirin are the 
only effective measures available to our medical practitioners today.  The development of 
vaccines and antivirals has long been hampered by the lack of any tissue culture adapted viruses.  
This forced researchers to rely on replicon-harboring cells based upon either the full length HCV 
genome or smaller subgenomic replicon systems (102).  Recently both genotype I and II viruses 
have been isolated that were successfully tissue culture adapted giving researchers there first 
chance to work with a replication competent HCV viral system (101, 212). 
 
A number of antiviral compounds have been identified against HCV through the use of replicon-
harboring cells, and there are currently a number of antiviral compounds being evaluated for 
their efficacy against HCV both in the lab and in clinical trials (37, 58, 104, 131).  Groups of 
specifically targeted antiviral therapies against HCV include antivirals specifically targeted 
against two main proteins within HCV: NS5B the RNA-dependent RNA-polymerase, and NS3 
the viral protease.  The rapid mutation rate of the HCV genome has currently prevented the 
development of a viral specific antiviral that the virus is unable to escape.  The escape potential 
of HCV requires the continuous development of new antivirals.  A second group of HCV 
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antivirals based upon the inhibition of cellular factors that are essential to viral replication are 
also being developed.  The prototypical member of this family is cyclosporine A (58, 131).  
Cyclosporine A has been shown both in vivo and in vitro studies to significantly reduce the 
overall HCV levels.  The downside of Cyclosporine A is its immunosuppressive effects.  
Currently a number of non immunosuppressive derivatives including Debio-25 and NIM811 
have been synthesized and are being evaluated for their anti-HCV potential in various clinical 
trials (37, 104). 
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Figure 1-1. The PRRSV Virion.  
A) The Structure of the PRRS Virion B) Genomic Organization of PRRSV C) Replication of 
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Figure 1-2. The HCV Virion.   
A) The structure of the HCV virion. B) Genomic organization of HCV C) Replication of HCV 
within the host cell. 
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Figure 1-3. The ERK Pathway. 
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CHAPTER 2 -  Modulation of CD163 Receptor Expression and 
Replication of Porcine Reproductive and Respiratory Syndrome 
Virus in Porcine Macrophages 
Abstract 
 
Porcine reproductive and respiratory syndrome virus (PRRSV) has a specific cell tropism for 
differentiated macrophages, such as porcine alveolar macrophages (PAMs).We analyzed the 
expression of CD163 on PAMs and macrophages derived from CD14 positive blood monocytes 
(MDMs), in correlation with PRRSV replication. By flow cytometry analysis, we showed that 
the levels of CD163 expression correlated well with the overall level of PRRSV replication. We 
further examined the effects of modulators of macrophage function, including 12-O-
tetradecanoylphorbol-13-acetate (TPA), lipopolysaccharide (LPS), and interleukin (IL)-10 on the 
expression of CD163 and PRRSV replication. Pre-treatment of PAMs or MDMs with TPA or 
LPS resulted in decreased expression of CD163 and reduction in PRRSV replication.  On the 
contrary, the incubation of CD14 positive monocytes with IL-10 during differentiation into 
MDMs resulted in up-regulated expression of CD163 with a corresponding increase in PRRSV 
infection. These data indicate that the expression of CD163 on macrophages in different 
microenvironments, in vivo, may determine the replication efficiency and subsequent 
pathogenecity of PRRSV. 
Introduction 
 
Porcine reproductive and respiratory syndrome (PRRS), caused by PRRS virus (PRRSV), was 
first described in the United States in 1987 (23) and a few years later in the Netherlands (52). 
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PRRSV is a member of the family Arteriviridae, which is composed of a group of positive sense, 
single stranded RNA viruses, including simian hemorrhagic fever virus (SHFV), equine arteritis 
virus (EAV), and lactate dehydrogenase-elevating virus (LDV) (5, 6, 28, 29, 55). At present, 2 
genotypes of PRRSV have been described: European (Type I), and North American (Type II). 
Sequence analysis has shown approximately a 60% nucleotide identity exists between the Type I 
and Type II genotypes (16, 20, 31, 35). Both genotypes have since been identified as a major 
viral pathogen in swine causing reproductive failure, respiratory distress, and a decrease in 
average weight gain, and are responsible for over 560 million dollars in losses per year in the 
United States alone (33). The PRRSV virion contains a genome of approximately 15 kb in length 
that encodes at least nine open reading frames (6). The genome is completed with the addition of 
a 5’ cap and 3’ poly(A) tail (29). The major and minor structural proteins are encoded by a 
nested set of subgenomic RNAs located on the 3’ end of the genome. The major structural 
proteins consist of the nucleocapsid (N) and membrane protein (M) as well as the major 
envelope glycoprotein (GP5), and the minor structural proteins include GP2a, GP2b, GP3, and 
GP4 (8, 54). 
 
PRRSV has a tropism for cells of the monocytic lineage, especially differentiated macrophages 
such as porcine alveolar macrophages (PAMs) (21). PRRSV primarily replicates in PAMs, but it 
has been identified in macrophages located in tissues including spleen, liver, Peyer’s patches, 
and thymus (26, 27, 37). PRRSV isolates can be serially passaged in vitro in immortal cell lines 
derived from MA104 (African green monkey kidney) cells, including MARC-145  (1, 24). 
However, there remain gaps in our knowledge regarding the factors that regulate cell tropism.  
Several receptors for PRRSV have been described, including heparin sulfate, sialoadhesin, and 
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vimentin (9, 10, 24). Recently, CD163, a molecule that is expressed exclusively on cells of a 
monocytic lineage, has been identified as a possible cellular receptor for PRRSV (4). Calvert et 
al. (2007) identified CD163 as a receptor that allowed previously nonpermissible cells to become 
susceptible to PRRSV infection. CD163 is a hapten/hemaglobin scavenger receptor in the 
scavenger receptor cysteine-rich (SRCR) superfamily (38, 40, 53).  CD163 is currently thought 
to be involved in anti-inflammatory responses and the removal of haptoglobin and hemoglobin 
from the blood (17). The expression of CD163 on macrophages is inducible and can be either up- 
or down-regulated by treatment with different stimuli including interleukin (IL)-10, 
dexamethasone, macrophage colony-stimulating factor (M-CSF), granulocyte-macrophage 
colony-stimulating factor (GM-CSF), and IL-4 (2). In addition to the surface expression of 
receptor and co-receptor molecules, other factors appear to be necessary for PRRSV 
permissiveness (3).  
 
In this report, we provide further evidence for CD163 being a PRRSV receptor. First, we 
demonstrate that a non-permissive cell line, LLC-PK, can be made permissive for PRRSV 
replication by expression of a full-length porcine CD163. Second, we found that an anti-CD163 
monoclonal antibody could reduce the infection levels of PRRSV in PAMs. Third, we show that 
surface expression of CD163 on PAMs and CD14 positive monocyte-derived macrophages 
(MDMs) can be modulated following treatment with IL-10, LPS, or TPA. Finally, the expression 
level of CD163 correlates with the level of PRRSV infection. These data suggest that the 
expression of CD163 on macrophages in different microenvironments in vivo possibly may 
determine the replication levels of PRRSV and the virus pathogenicity. 
Materials and Methods 
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Cells and Reagents 
 
MARC-145 and LLC-PK cells were maintained in Eagle’s minimal essential medium (EMEM, 
Mediatech, Herndon, VA) containing 5% fetal bovine serum and antibiotics [penicillin (250 
U/ml) and streptomycin (250 µg/ml)]. PAMs and MDMs were maintained in RPMI-1640 
(Mediatech) supplemented with 10% fetal bovine serum (FBS) and antibiotics. 12-O-
Tetradecanoylphorbol-13-acetate (TPA) and lipopolysaccharide (LPS) were obtained from 
Sigma–Aldrich (St. Louis, MO). TPA or LPS was reconstituted in DMSO or distilled water at 50 
mM or 10 mg/ml, respectively. Recombinant IL-10 and GMCSF were obtained from R&D 
systems (Minneapolis, MN) and was reconstituted in PBS. An anti-PRRSV nucleocapsid 
antibody conjugated with FITC (SDOW17) was obtained from South Dakota State University 
(Brookings, SD). Antibodies to porcine CD14 and CD163 were purchased from AbD Serotech 
(Raleigh, NC). PRRSV strains, SD01-08 (SDSU, Type I) (12, 13) and P129 (Type II, isolated 
and characterized at the Animal Disease Diagnostic laboratory, Purdue, West Lafayette, IN, 
Calvert et al., 2002 [GenBank Accession #AF494042]) were maintained by passaging in MARC-
145 cells. The PRRSV expressing GFP (129-GFP) was generated by transfecting the Kermit 
(Yoo et al., 2004) infectious clone (Pfizer Animal Health, Kalamazoo, MI) in MARC-145 cells 
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Virus stocks were prepared and titered in 
MARC-145 cells and stored in aliquots at −80oC until use. 
Generation of Virus Stocks 
 
All virus isolates were cultured on 2–3-day-old confluent layers of MARC-145 cells in T-75 
flasks. Virus was allowed to propagate until 70–80% CPE was observed and each flask was 
frozen and thawed 2 times to ensure cell lysis. Supernatant was then collected and aliquotted 
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before being stored at −80oC until use. Viral titers were determined by titration on MARC-145 
cells. All experiments were carried out using a multiplicity of infection (MOI) of 1, as 
determined by titration on MARC-145 cells 
Generation of LLC-PK Cells Constitutively Expressing CD163 
 
The full length porcine CD163 was amplified from the total RNA of PAMs using RT-PCR with 
primers pCD163-Nhe-F (aattGCTAGCATGGACAAACTCAGAATGGTGC, Nhe1 restriction 
sequence underlined) and pCD163-Not-R  
(aattGCGGCCGCTCATTGTACTTCAGAGTGGTCTCC, Not1 restriction sequence 
underlined). Total RNA of PAMs was isolated using the RNeasy kit (Qiagen, Valencia, CA) and 
RT-PCR reactions were performed using the Titan RT-PCR kit (Roche, Indianapolis, IN). The 
amplified CD163 cDNA (∼3.6 kb) was cloned into pIRES-Puro2 (Clonetech, Los Angeles, CA) 
using Nhe I and Not I restriction sites. After the construct was verified by sequence analysis, the 
plasmid was transfected into 1-day-old semi-confluent LLC-PK cells using Lipofectamine 2000 
(Invitrogen). LLC-PK cells expressing porcine CD163 were selected using 4µg puromycin per 
ml of MEM containing 10% FBS. The media containing puromycin was replenished every 3–4 
days during selection. After selection, individual cell clones were isolated in a limiting dilution 
method using 96 well plates, and the resulting colonies were screened for the expression of 
CD163 by immunofluorescent assay (IFA) using anti-porcine CD163. Several cell clones 
expressing high levels of CD163 were chosen and designated as LLC-PK-CD163. Further IFAs 
were performed using SDOW17 in the parental LLC-PK and LLC-PK CD163 cells to measure 
for PRRSV susceptibility using virus strains P129 and SD01-08.  Two- or three-day-old 
confluent cells were inoculated with each PRRSV strain at a MOI of 1 and incubated for 24 h. 
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IFA staining was performed after the cells were fixed with 80% acetone. P129-GFP was also 
used to examine the infectivity of PRRSV in the cells by observing GFP expression on a 
fluorescent microscope. 
Preparation of PAMs and MDMs Derived From CD14 Positive Cells 
 
Porcine alveolar macrophages were collected from 7 to 8-weekold PRRSV negative pigs by lung 
lavage with phosphate buffered saline (PBS) during necropsy. Collected cells were washed 3 
times in PBS and pelleted by centrifugation at 300×g for 10min. Cells were frozen at a 
concentration of 2×107 cells/ml in liquid nitrogen until use. The frozen PAMs were rapidly 
thawed in a water bath (37oC), washed in 10ml of PBS, and resuspended in RPMI containing 
10% charcoal/dextran treated FBS (HyClone, Logan, Utah). The CD14 positive porcine 
monocytes were isolated from the whole blood of 7–8-week-old PRRSV negative pigs. The 
collected whole blood was overlayed on a ficoll gradient (Sigma–Aldrich) to isolate peripheral 
blood mononuclear cells (PBMC). The isolated PBMCs were stored at a concentration of 1×108 
cells/ml in liquid nitrogen. CD14 positive cells were then isolated from the PBMC using 
magnetic assisted cell sorting (MACS, Miltenyi Biotech, Auburn, CA) and a monoclonal 
antibody against porcine CD14. Briefly, cells (PBMC) were rapidly thawed and washed 2 times 
in PBS and collected by centrifugation at 300×g for 7 min. Cells were resuspended in 160µl of 
2% FBS in PBS with 200mM EDTA (wash solution).  Anti-porcine CD14 antibody (30µl) was 
then added and incubated on ice for 20 min. Cells were brought up in 10 ml of the wash solution 
and rinsed one time before collection at 300×g for 7 min. The antibody bound cells were 
resuspended in wash solution containing magnetic beads coated with anti-Mouse IgG (Miltenyi 
Biotech) and incubated on ice for 20 min. After incubation, cells were rinsed once in wash 
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solution, and applied onto a Millityec MACS sorter. CD14 positive cells were eluted in 1ml 
RPMI-1640. The isolated CD14 positive monocytes were resuspended in RPMI-1640 containing 
10% charcoal/dextran treated FBS and antibiotics.  The CD14 positive cells were allowed to 
differentiate into macrophages (MDMs) for up to 4 days in the presence of 10 ng/ml GM-CSF. 
The Expression of CD163 and PRRSV Susceptibility in PAMs or MDMs 
 
The population of PAMs or MDMs expressing CD163 at various stages were examined in 
correlation with PRRSV infectivity. To accomplish this, freshly isolated (day 0) or 1–3-day-old 
PAMs or MDMs were plated at 5×105 cells/well in a 6 well plate and inoculated with P129-GFP 
at a MOI of 1. Virus infected cells were incubated for 18 h before the expression of CD163 or 
GFP was measured by flow cytometry analysis as described below. 
Treatment of anti-CD163 Monoclonal Antibody on PRRSV Infection in PAM 
 
PAMs were incubated in dilutions of mouse anti-porcine CD163 antibody of 0, 1, 3, or 5 
µg/100µl media in a total volume of 200 µl of complete media. Non-specific (NS) monoclonal 
antibody to anti-Norwalk virus VP1 (Chemicon, Temecula, CA) was used at 5 µg/100µl as a 
control antibody. After an additional incubation of 18 h, GFP positive cells were collected for 
flow cytometry, and virus titers were measured as TCID50/ml. For flow cytometry cells were 
washed with PBS and trypsinized before being fixed in 4% paraformaldhyde and resuspended in 
250µl of PBS for analysis as described below. The virus titration (50% tissue culture infectivity 
dose, TCID50) was performed as described below. 
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Treatments of MARC-145, PAMs, MDMs or CD14 Positive Monocytes with IL-10, 
TPA or LPS 
 
MARC-145, PAMs, MDMs, or CD14 positive monocytes were treated with mock-EMEM, 
DMSO (0.1%), IL-10, TPA, or LPS to examine their effects on the expression of CD163 and 
PRRSV infectivity. In this study, LPS, TPA, or IL-10 was used at a concentration of 5 µg/ml, 50 
µM, or 10 ng/ml, respectively. Trypan blue exclusion staining showed no cytotoxic effects at the 
concentrations used. Confluent MARC-145 cells were pretreated with mock-EMEM, DMSO, IL-
10, TPA, or LPS for 2 h and then P129 was inoculated at a MOI of 1 for 1 h. The medium was 
then replaced with fresh medium containing the same treatment and incubated for additional 24, 
48, or 72 h. After each time point, virus growth was enumerated by TCID50 assay using MARC-
145 cells. 
 
For PAMs, cells were plated in 24-well plates at 5×105 cells/ml for 24 h before treatment with 
mock-EMEM, DMSO, IL-10, TPA, or LPS for 2 h. After the initial treatment, cells were 
infected with mock-medium, P129, or P129-GFP at a MOI of 1 and incubated in the presence of 
the same treatment for up to 72 h. The expression of CD163 and/or GFP was examined at 18 h 
after virus infection (P129-GFP) by flow cytometry. Virus (P129) growth was also measured at 
12, 24, 48, and 72 h post-infection using TCID50 assays in MARC-145 cells. For MDMs, CD14 
positive cells (5×105 cells/ml in 24-well plates) were differentiated to macrophages in the 
presence of FBS and GM-CSF (10 ng/ml) for 3 days and then treated with each agent for 2 h 
before the inoculation with mock-medium, P129, or P129-GFP. After virus inoculation, cells 
were incubated in the presence of the same treatment for up to 72 h. Alternatively, freshly 
isolated CD14 positive monocytes (undifferentiated) (5×105 well-1 in 12-well plates) were 
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incubated in the presence of mock-EMEM, DMSO, TPA, IL- 10, or LPS in medium containing 
FBS and GM-CSF for 72 h. They were then inoculated with mock-medium, P129, or P129-GFP 
and further incubated for up to 72 h. The expression of CD163, GFP, or virus growth was 
measured at the same time points as PAMs. 
Flow Cytometry Analysis for the Expression of CD163 or GFP 
 
Flow cytometry analysis was used to compare the overall expression levels of CD163 and the 
infection levels of P129-GFP in PAMs and MDMs. All flow cytometry analysis was performed 
on a population of 10,000 cells using the FACS Calibur system (BD Bioscience, Franklin Lakes, 
NJ). Cells were prepared for flow cytometry analysis using the following protocol. Adherent 
cells were removed from the plate by incubation in 5mM EDTA/PBS for 2 h. Cells were washed 
with PBS and collected by centrifugation at 300×g for 10 min before being fixed with a 4% 
paraformaldehyde solution (Electron Microscopy Science, Hatfield, PA) while incubating on ice 
for 1 h. After the cells were washed in PBS, they were incubated with mouse anti-swine CD163 
in PBS with 5% FBS on ice for 1 h. Cells were then washed in PBS and incubated in 5% 
FBS/PBS with a secondary R-Phycoerythrin conjugated (RPE) anti-mouse IgG1 antibody 
(Invitrogen) for 1 h. After washing the cells, they were analyzed for the presence of RPE on the 
flow cytometer. The same cells were also enumerated for the expression of GFP. Either single or 
dual color analysis was performed for RPE and/or GFP. 
 
Data analysis of the flow cytometry data was performed using CellQuestTM (BD Bioscience). 
The appropriate gates were set using control cells which included cells without any treatment, 
PRRSV infected cells, and/or cells stained with only secondary conjugates. All quadrant gates 
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showing the expression of CD163 (RPE, y-axis) and GFP (PRRSV infection, x-axis) were set 
using fixed cells only allowing for a maximum of a 1% overlap into any of the other three 
quadrants. These gate settings were checked against cells stained with only secondary conjugates 
and virus infected cells to ensure that they were appropriate for the experiment. Quadrant 
statistics were obtained for the generation of the data sets in each figure. Positive populations 
were identified as cells showing an increased florescence intensity level from the control cell 
populations, and overall percentage levels of positive cells were calculated based on the quadrant 
gates. 
PRRSV Titration 
 
TCID50 assay was used for the PRRSV titration to examine the effects of the treatment on virus 
replication in MARC-145, PAMs, CD14 positive monocytes, and MDMs. The titration was done 
after virus infected cells were freeze-thawed twice to ensure complete cell lysis. After 
centrifugation, the supernatant was assayed using the standard method on MARC-145 cells. 
Statistical Analysis 
All experiments were done with at least three independent experiments and statistical 
significance (p < 0.05) was calculated with the Students’ t-test. 
Results 
LLC-PK Cells Expressing CD163 Support the Replication of PRRSV 
 
The full length CD163 cDNA (∼3.6 kb, Fig. 2-1) was recovered from PAMs by RT-PCR, and 
cloned into pIRES-Puro2. LLC-PK-CD163 cells that were selected in the presence of puromycin 
(4 µg/ml) had similar growth kinetics as the parental cells (LLC-PK) with the majority of them 
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expressing CD163 (>80%) as confirmed by immunofluorescent assay (IFA) using an antibody 
against porcine CD163 (data not shown). 
 
When parental LLC-PK cells were inoculated with either PRRSV strains P129 (or P129 strain 
carrying GFP gene [P129-GFP]) or SD01-08, there was no evidence of virus replication at 12, 
24, or 48 h by IFA with SDOW17 (an anti-PRRSV nucleocapsid antibody conjugated with 
fluorescein isothiocyanate [FITC]) or GFP expression (Fig. 2-2). It has been demonstrated that 
the infectivity of P129-GFP is comparable to that of parental P129 (55). LLC-PK cells supported 
PRRSV replication when transfected with a P129 infectious cDNA, indicating that the lack of 
permissiveness was the result of the absence of a receptor on the cell surface. PRRSV replication 
was observed in LLC-PK-CD163 after inoculation with P129, P129-GFP or SD01-08 (Fig. 2). 
PRRSV infected cells were detected after 12 h with increasing numbers at 24 h with the 
appearance of fluorescent foci. By 48 h post-infection, the majority of cells were infected with 
PRRSV determined by IFA or observation of GPF expression. The course of infection correlated 
with the progression of CPE. However, neither fluorescence or CPE was observed in parental 
LLC-PK cells after infection with PRRSV strains (Fig. 2). These data confirm the observations 
of Calvert et al. and further support the notion that expression of CD163 can make cells 
permissive for PRRSV replication. 
CD163 Expression Correlates with PRRSV Infectivity in Cells of Monocyte Origin 
 
We utilized dual color flow cytometry to analyze PRRSV replication and CD163 expression in 
PAMs and MDMs during infection with PRRSV. For these experiments, surface CD163 
expression was measured using RPE-labeled antibody, and virus replication in individual cells 
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was detected by the presence of GFP following infection with P129-GFP. Cells were infected at 
different times after placement into culture, and flow cytometry was performed 18 h later just 
prior to lysis of infected cells. For PAMs, a majority of cells expressed high levels of CD163 
from days 0 to 3 (Fig. 2-3A). At day 0, over 60% of PAMs were CD163 positive. By days 2 and 
3, the percentage of CD163 positive cells increased to more than 70%. The percentage of PAMs 
expressing GFP after the inoculation with P129-GFP was also high and ranged from 20 to 30% 
(Fig. 2-3B). After 48 h, the majority of virus infected PAMs were lysed (data not shown), 
indicating that most of cells were eventually infected with PRRSV. For CD14 positive 
monocytes, the expression level of CD163 was less than 10% at Day 0 (Fig. 2-3C). However, as 
cells were differentiated to MDMs, the population expressing CD163 steadily increased, 
reaching nearly 70% by day 3 (Fig. 2-3). The increased percentage of CD163 positive cells was 
not the result of CD163 negative cells dropping out, since cell numbers remained relatively 
constant over the culture period. A similar pattern was observed for the percentage of cells 
expressing GFP after infection (Fig. 2-3D). While there were few GFP expressing MDMs among 
cells at day 0, over 30% of cells were expressing GFP when incubated in culture longer than 2 
days (Fig. 2-3D). 
Anti-Porcine CD163 Antibody Reduced PRRSV Infection in PAMs 
 
PAMs were incubated with various concentrations of anti-porcine CD163 antibody. At 18 h post-
infection flow cytometry analysis showed that anti-porcine CD163 was capable of blocking virus 
infection in a dose dependent fashion. At the concentrations of 5µg/100µl or 3µg/100µl anti-
porcine CD163 antibody reduced overall infection rate by 19.4% or 8%, respectively (Fig. 2-
4A). However at the level of 1µg/100µl, the antibody showed little effect on PRRSV infection 
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(Fig. 2-4A and 2-B). Control monoclonal antibody (anti-Norwalk virus VP1) did not change the 
level of GFP expression.  The TCID50 results confirmed that GFP expression showing that there 
were greater than a 1.5 log difference at 5µg/100µl, and 1 log difference at 3µg/100µl anti-
porcine antibody when compared to mock-treatment (Fig. 2-4B). These data suggest that the 
expression CD163 in PAM plays a significant role in determining the cells susceptibility to 
PRRSV infection. 
Correlation of CD163 Expression and PRRSV Infectivity 
 
Because the expression of CD163 can be modulated by various cytokines and reagents, we 
examined the effects of IL-10, TPA, or LPS on CD163 expression and PRRSV infection on 
MARC-145, PAMs or MDMs. For these experiments, mock-treated cells were incubated with 
DMSO, the solvent used to dissolve the TPA. There were no significant differences in CD163 
expression (89%±2 vs. 90%±3) and GFP expression (34%±3 vs. 29%±11) when PAMs were 
infected with P129-GFP and treated with mock-medium or DMSO (0.1%).  Therefore, we used 
DMSO-treatment as a control for comparison.  The treatment of MARC-145 cells with TPA, IL-
10, or LPS did not yield any significant differences in PRRSV replication as measured by virus 
yield (Fig. 2-5). However, after a 2 hr treatment with TPA, PAMs showed a reduction in the 
percentage of cells expressing CD163 (22%) and GFP (15%; Fig. 6A and Table 1). 
 
The decreased percentage of dual positive cells in the TPA treated cultures corresponded with a 
significant decrease in virus yield, when measured at 12 and 24 h after infection (p < 0.05; Fig. 
2-6B).  The PAMs treated with IL-10 and LPS and infected with P129-GFP did not show 
significant changes in the overall expression of CD163 or GFP (Fig. 2-6A and Table 2-1). It was 
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observed that PAMs treated with LPS frequently yielded a reduced titer (about 0.7 log) at 12 h 
after virus infection, but was not significantly different over several experiments (Fig. 2-6B). The 
treatment of PAMs with IL-10 showed no significant changes in virus titers at any of the time 
points (Fig. 2-6A and Table 2-1). At 36 h post-infection, there was no significant difference in 
virus titers among the various treatments (Fig. 2-6B). 
Modulation of CD163 on MDMs and PRRSV Infectivity 
 
The effects of TPA, LPS or IL-10 on CD163 and PRRSV infectivity were examined in 
differentiated MDMs, or freshly isolated CD14 positive monocytes undergoing differentiation. 
Differentiated MDMs were prepared by incubating freshly isolated CD14 positive monocytes in 
the presence of 10 ng/ml GM-CSF for up to 4 days. Similar to PAMs, differentiated MDMs 
infected with P129-GFP after treatment with TPA demonstrated a significant (p < 0.05) 
reduction in the overall population expressing CD163 compared to mock(DMSO)-treated cells. 
This reduction correlated with the reduced number of GFP expressing cells (Fig. 2-7A and Table 
2-1). Similar to PAMs, there was a subpopulation of cells that expressed relatively high levels of 
CD163, but were GFP negative. In addition, another subpopulation of cells expressed relatively 
low levels of CD163 on their surface, but were GFP positive. The cells expressing high levels of 
CD163 and low levels of GFP may represent the use of an alternative receptor, or perhaps the 
down regulation of surface CD163 expression following infection. Treatment of differentiated 
MDMs with LPS also reduced the percentages of CD163 and GFP expressing cells (Fig. 2-7A 
and Table 2-1). Differentiated MDMs treated with IL-10 and then infected with P129-GFP did 
not yield significant changes in the populations expressing CD163 or GFP (Fig. 2-7A and Table 
2-1). Virus titers after each treatment and P129-GFP infection in the differentiated MDMs 
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correlated well with the expression of CD163 and GFP with the lowest virus yields obtained 
from cultures treated with TPA and LPS (Fig. 2-7B). 
 
Experiments were also performed in freshly isolated CD14 positive monocytes incubated with 
GM-CSF in combination with DMSO, TPA, LPS, or IL-10, which resulted in drastic changes in 
the expression of CD163 and PRRSV infectivity. The treatment of freshly isolated CD14 
positive monocytes with TPA or LPS resulted in the reduction of the number of cells expressing 
CD163 to less than 5% from approximately 50% of the control (Table 2-1). Interestingly, 
treatment of freshly isolated CD14 positive monocytes with IL-10 for 72 h significantly 
increased (p < 0.05) the numbers of cells expressing CD163 compared to the treatment with 
DMSO (Fig. 2-8A and Table 2-1). The titers of PRRSV after each treatment on freshly isolated 
CD14 positive monocytes also correlated with the overall levels of CD163 expressing cells (Fig. 
2-8B and Table 2-1). The treatment of IL-10 significantly increased (p < 0.05) the PRRSV titers 
up to 1.5-fold at 12, 24, or 48 h after virus inoculation, the treatment with TPA or LPS yielded 
less than 1 log TCID50 titers at all time points (Fig. 2-8B). 
Discussion 
 
PRRSV has a cellular tropism for cells of monocytic lineage, especially differentiated 
macrophages, such as porcine alveolar macrophages (21). Several putative receptors for PRRSV 
have been described, including heparin sulfate  (10), sialoadhesin  (9), and vimentin (24). 
Delputte et al. (10) identify heparin sulphate as a binding receptor on macrophages for both Type 
I and II PRRSV strains. However, it is not believed that heparin sulphate mediates the 
internalization of PRRSV(10). Porcine sialoadhesin has been identified as the molecule 
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responsible for the internalization of the PRRSV virion  (9, 48). Monoclonal antibodies directed 
against sialoadhesin can prevent the internalizing the virus in cells (9). Kim et al. (24) reported 
that a monoclonal antibody (7G10) which binds vimentin has the ability to block PRRSV 
infection in MARC-145 cells, suggesting that it may be a possible receptor on MARC-145 cells 
(24). Recently, CD163 has been identified as a possible cellular receptor for PRRSV (4). Using a 
cDNA library created from total RNA isolated from PAMs, Calvert et al. (4) were able to 
identify CD163 as a receptor which allowed previously non-permissible cells to become 
susceptible to PRRSV infection with the expression of CD163. They demonstrated that this 
molecule alone could produce a fully susceptible cell line for both Type I and II PRRSV isolates 
(4). In this report, we confirmed CD163 as a receptor for PRRSV with the generation of a 
susceptible LLC-PK-CD163 cell line. This stable cell line expressing CD163 also fully 
supported the PRRSV strains of both Type I (SD01-08) and Type II (P129). The CD163 that was 
isolated in this study from total RNA of PAMs was the full length mRNA containing all 9 SRCR 
domains which was slightly different from a CD163 splice variant with 7 SRCR domains used 
by Calvert et al. (2007). Our study demonstrates that as a receptor for PRRSV, CD163 alone 
(either a full length or a variant) can bind and internalize the viruses for successful infection. 
 
CD163, formerly known as M130 and RM3/1, has been identified as a hapten/hemaglobin 
scavenger receptor in the SRCR superfamily (38, 39, 53).  There are 2 known porcine splice 
variants (susCD163v1 [Genbank: DQ067279] and susCD163v2 [Genbank: NM 213978) 
encoding for CD163 that have currently been identified in swine, while a number of variants 
have been identified in humans (4). The predominant mRNA form encodes an open reading 
frame of 3348 bp which consists of 9 SRCR domains, a transmembrane segment of 24 amino 
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acids, and a cytoplasmic tail comprised of 49 amino acids (18, 39).  CD163 is currently thought 
to be involved in anti-inflammatory responses and the removal of haptoglobin and hemoglobin 
from serum (17). Interestingly, among macrophages from various tissues, the expression of 
CD163 was highest on alveolar microphages and macrophages in the term placenta (17). This 
may correlate with the major symptoms of PRRSV in animals: respiratory symptoms and 
abortion. 
 
Although CD163 is known to be expressed on monocyte lineages, not much is known regarding 
its expression levels on PAMs and MDMs in the correlation with PRRSV infectivity. As 
expected, a high number of PAMs that expressed CD163 were susceptible to PRRSV infection 
regardless of incubation times in vitro (Fig. 2-3A and B). On the other hand, most of the freshly 
isolated monocytes did not express CD163 and were not susceptible to PRRSV infection (Fig. 2-
3C and D). The expression of CD163 on MDMs was dependent on the differentiation levels and 
correlated well with PRRSV susceptibility in our study (Fig. 2-3C and D). Blocking assays with 
anti-porcine CD163 antibodies also suggested that CD163 may be the receptor on PAM that is 
responsible for its susceptibility to PRRSV (Fig. 2-4A and B). These studies suggested that the 
overall expression levels of CD163 on both PAMs and MDMs may determine the levels of 
PRRSV replication and pathogenicity in vivo. It would be interesting to examine the expression 
levels of CD163 on the macrophages from different tissues and the correlation with PRRSV 
infection. 
 
To further demonstrate evidence of the correlation between CD163 expression levels and 
PRRSV infectivity in PAMs and MDMs, we modulated the expression of CD163 on the cells 
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and examined the effects on virus replication. It has been demonstrated that the expression of 
CD163 on macrophages can be up-regulated by glucocorticoids and anti-inflammatory cytokines 
such as IL-10, while down-regulated by pro-inflammatory mediators such as LPS, interferon 
(IFN)-α, and tumor necrosis factor (TNF)-α  (2). Therefore, we examined the effects of TPA, IL-
10, or LPS on CD163 expression and PRRSV infection in MARC-145 cells, PAMs, or MDMs. 
We found that the treatment of in MARC-145 cells with TPA, IL-10, or LPS did not show 
significant differences in PRRSV susceptibility, indicating these cells may be lacking the 
pathway for CD163 modulation and that these agents did not affect PRRSV infectivity. It has 
been previously demonstrated that the treatment of macrophages with protein kinase C activators 
such as TPA or phorbol 12-myristate 13-acetate (PMA) causes a reduction in the surface 
expression of CD163 (22). Furthermore, Duan et al. (11) reported that the treatment of 
monocytes and macrophages with PMA reduced replication of PRRSV. Our results are 
consistent with the data, demonstrating the treatment of PAMs or MDMs with TPA reduces the 
population of cells expressing CD163 with a concurrent reduction of PRRSV susceptibility 
(Figs. 2-5–7). Previously, Buechler et al. (2) showed that LPS down-regulated CD163 expression 
on macrophages. In this study, while the treatment of PAMs with LPS did not cause a significant 
reduction of CD163, the treatment of differentiated MDMs with LPS significantly reduced the 
population expressing CD163 in correlation with the reduction of PRRSV infectivity (Fig. 2-7 
and Table 2-1). The effects of TPA or LPS on CD163 expression and PRRSV infection were 
more obvious when CD14 positive monocytes were treated during differentiation into MDMs 
(Fig. 2-8). The treatment of these differentiating cells with TPA or LPS for 72 h yielded a drastic 
decrease in the population of cells expressing CD163 (Fig. 2-8). The expression of GFP (after 
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P129-GFP infection) and PRRSV titers were nearly undetectable (Fig. 2-8).  Our results suggest 
that TPA or LPS may impair differentiation of monocytes and/or the expression of CD163. 
 
Cytokines play an important role in the regulation of the overall immune response, both 
enhancement and inhibition. IL-10, an anti-inflammatory cytokine, has been shown to inhibit the 
activation of a number of cells involved in the immune response including T cells, monocytes, 
and macrophages. IL-10 can inhibit the expression of various cytokines by monocytes and 
macrophages including IL-1α, IL-1β, IL-6, IL-12, IL-18, GM-CSF, M-CSF, TNF, leukemia 
inhibitory factor (LIF) and platelet-activating factor (PAF) (7, 14, 19, 50, 51). The primary role 
of IL-10 appears to be the termination of the inflammatory response (43). Several different 
viruses including Epstein-Barr, equine herpes virus type 2, poxvirus Orf virus, and human 
cytomegalovirus encode an IL-10 homolog suggesting an important role in their replication 
cycles (15, 25, 30, 42, 49). In this study, we found that the incubation of freshly isolatedCD14 
positive cells with IL-10 during differentiation increased the susceptibility to PRRSV infection in 
correlation with the up-regulation of CD163 on the cell surface (Fig. 2-7). This suggests a 
significant role for IL-10 in CD163 and PRRSV susceptibility during the differentiation of 
macrophages in vivo. However, the treatment of PAMs and differentiated MDMs with IL-10 did 
not significantly change overall expression levels of CD163 and PRRSV infectivity. This may be 
due to the fact that most of these cells were already expressing CD163. Interestingly, it has been 
shown that the endocytosis of CD163 upon stimulation with hemoglobin or haptaglobin has the 
ability to increase the overall production of IL-10 (34). It is possible that the internalization of 
PRRSV via CD163 in the target cells may induce the expression of IL-10, and in turn induce the 
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expression of CD163 on neighboring undifferentiated monocytes and increase overall PRRSV 
susceptibility. We are currently studying this possibility using PAMs and MDMs. 
 
Proinflammatory cytokines such as IL-1β, IL-8 and TNF-α have been shown to be upregulated 
after treatment of monocytes or macrophages with LPS (32, 41). LPS plays an important role in 
PRRSV infections probably due to coinfections with gram negative bacteria. Coinfection of 
PRRSV and other microbes such as Mycoplasma hyponeumoniae  (45), Streptococcus suis  (46), 
and type 2 porcine circovirus  (44) is commonly observed in the field. It has been shown that 
coinfection with PRRSV and each of these pathogens can cause an increase of the overall gross 
pathology (36, 45-47). Pigs with a dual infection of PRRSV and M. hyponeumoniae exhibited an 
increased duration and severity of PRRSV infection (45). This may be due to the increased 
recruitment of monocytes caused by the pro-inflammatory cytokines in response to bacterial 
infections followed by anti-inflammatory cytokines such as IL-10 as the immune system tries to 
counter the inflammatory response. The modulation of the expression of CD163 on PAMs or 
MDMs by cytokines or other agents in vitro suggest that PRRSV susceptibility may be affected 
by the presence of such molecules due to inflammation or co-infections with various bacteria and 
viruses in the target tissue. In summary, our data demonstrated that CD163 alone can confer 
PRRSV replication in a non-permissible pig cell line, and the expression of CD163 on 
monocytes/macrophages in different microenvironments in vivo may determine the replication of 
PRRSV and the virus pathogenicity. Understanding the replication of PRRSV with the regulation 
of CD163 on the monocytes/macrophages in vitro and in vivo should provide important 
information regarding virus pathogenicity and preventive measures against the devastating 
disease. 
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Table 2-1. The Cell Population (%) Expressing CD163 or GFP After Each Treatment and 
Infection with P129-GFP for 18 h in PAMs, CD14 Positive Undifferentiated Monocytes or 
Differentiated MDMs.  
a The population expressing CD163 or GFP by the treatment was significantly 
different from that of mock(DMSO)-treatment (p < 0.05). 
 DMSO TPA LPS IL-10 
PAMs     
    CD163 90 ± 3 77 ± 6a 88 ± 3 91 ± 5 
    GFP 29 ± 11 14 ± 7a 25 ± 5 28 ± 9 
MDMs     
    CD163 85 ± 6 30 ± 15a 67 ± 11a 90 ± 3 
    GFP 34 ± 6 15 ± 13a 21 ± 13a 33 ± 9 
CD14 Positive     
    CD163 50 ± 3 1 ± 0.4a 1 ± 1a 78 ± 2a 
    GFP 15 ± 7 0.5 ± 0.3a 0.7 ± 0.5a 20 ± 8a 
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 Figure 2-1. mRNA and Structural Organization of CD163. 
CD163 is approximately 120 kDa in size and amember of the scavenger receptor cysteine-rich 
(SRCR) superfamily. It is composed of 3 primary domains including 9 SRCRdomains, a 
transmembrane region, and a short cytoplasmic tail. (A) The mRNA organization of CD163. (B) 
The structural organizations of CD163 with full 9 domains (upper panel) or a splice variant with 
7 domains (lower panel). 
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Figure 2-2. PRRSV Replication in Parental LLC-PK or LLC-PK-CD163 cells. 
Confluent parental LLC-PK or LLC-PK-CD163 cells were infected with P129 or P129-GFP for 
up to 48h, and virus replication was detected by IFA (A) or GFP expression (B). (A) LLC-PK or 
LLC-PK CD163 cells infected with P129 for 24 h. Fixed cells were incubated with SDOW17 
and observed under a fluorescent microscope. (B) LLC-PK or LLC-PK-CD163 cells infected 
with P129-GFP for 24 or 48 h, and observed under a fluorescent microscope (upper panel) or a 
light microscope (lower panel). 
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Figure 2-3. The Expression of CD163 and PRRSV Infectivity in PAMs and Differentiating 
CD14 Positive Monocytes. 
PAMs and freshly isolated CD14 positive monocytes were placed in culture for 0, 1, 2, and 3 
days, infected with PRRSV (P129-GFP) for 18 h and enumerated for the population expressing 
CD163 or GFP by flowcytometry. (A–D) The population expressing CD163 (A and C) or GFP 
(B and D) on 0, 1, 2, and 3-day-old PAMs (A and B) or differentiating CD14 positive monocytes 
(C and D). Bars represent standard error of at least three independent experiments in all figures. 
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Figure 2-4. The Effects of Anti-CD163 Antibody on the Infection of PAMs with P129-GFP. 
Cellswere incubated with 0, 1, 3, or 5µg anti-porcine CD163 antibody per 100µl complete 
medium for 1 h before infection with P129-GFP. Non-specific anti-Norwalk virus IgG was used 
as a control antibody. At 18 h post-infection the percentage of GFP-expressing cells was 
determined by flow cytometry. Cells were fixed with 4% paraformaldehyde before overall GFP 
expression was measured. Grey line represents untreated cells, each black line represents a 
treatment group. The left shift in each treatment group represents the overall decrease in GFP 
expression levels (4A). TCID50 levels were also measured 18 h post-infection (4B). Error bars 
represent the standard error of 3 separate experiments. Asterisk (*) indicates that the PRRSV 
titer by the treatment was significantly reduced from that of mock-treatment (p < 0.05). 
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Figure 2-5. The Effects of TPA, LPS, or IL-10 on PRRSV Infection in MARC-145. 
Confluent MARC-145 cells were pretreated with DMSO (mock-control), TPA (50µM), LPS 
(5µg/ml), and IL-10 (10 ng/ml) for 2 h before they were inoculated with P129 at a MOI of 1. The 
virus infected cells were further incubated in the presence of the same treatment for 24, 48, 72 or 
96 h, and TCID50 virus titerswere determined using MARC-145 cells. 
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Figure 2-6. The Effects of DMSO, TPA, LPS, or IL-10 on PRRSV Replication in PAMs. 
One-day-old PAMs (5×105 cells/well in 12-well plates) were treated with DMSO (mock-
control), TPA (50µM), LPS (5µg/ml), and IL-10 (10 ng/ml) for 2 h, and then they were 
inoculated with either mock-medium, P129 or P129-GFP at a MOI of 1 and incubated in the 
presence of the same treatment up to 36 h, and examined for the expression of CD163 or GFP 
and for virus replication. (A) The expression of CD163 (RPE [R-Phycoerythrin], y-axis) or GFP 
(x-axis) examined by flow cytometry analysis after the pretreated cells were infected with P129-
GFP for 18 h. This flow cytometry data is froma representative animal and a part of Table1. (B) 
PRRSV titers after the pretreated PAMs were infected with P129 for 12, 24 and 36 h. Asterisk 
(*) indicates that the PRRSV titer by the treatment was significantly reduced from that of mock-
treatment (p < 0.05). 
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Figure 2-7. The Effects of DMSO, TPA, LPS, or IL-10 on PRRSV Replication in 
Differentiated MDMs. 
Isolated CD14 positive monocytes were incubated in the presence of GM-CSF (10 ng/ml) and 
10% FBS for at least 3 days for the differentiation to macrophages. The differentiated MDMs 
were treated with DMSO(mock-control), TPA (50µM), LPS (5µg/ml), and IL-10 (10 ng/ml) for 
2 h, and then they were inoculated with either mock-medium, P129 or P129-GFP at a MOI of 1. 
Virus infected cells were further incubated for in the presence of the same treatment up to 24 h. 
(A) The expression of CD163 (RPE [R Phycoerythrin], y-axis) or GFP (x-axis) examined by 
flow cytometry analysis after the pre-treated cells were infected with P129-GFP for 18 h. This 
flow cytometry data is from a representative animal and a part of Table 1. (B) PRRSV titers after 
the pretreated MDMs were infected with P129 for 12 and 24 h. Asterisk (*) indicates that the 
PRRSV titer by the treatment was significantly reduced from that of mock-treatment (p < 0.05). 
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Figure 2-8. The Effects of DMSO, TPA, LPS, and IL-10 on PRRSV Replication in CD14 
Positive Monocytes. 
Freshly isolated CD14 positive monocytes were treated with DMSO (mock-control), TPA 
(50µM), LPS (5µg/ml), and IL-10 (10 ng/ml) for 72 h, and they were inoculated with either 
mock-medium, P129 or P129-GFP at a MOI of 1. Virus infected cells were further incubated in 
the presence of the same treatment for up to 72 h. (A) The population expressing CD163 after the 
pretreated cells were infected with P129-GFP for 18 h. (B) PRRSV titers after the pretreated 
CD14 positive monocytes were infected with P129 for 24, 48 and 72 h. Asterisk (*) indicates 
that the population expressing CD163 (A) or the PRRSV titer (B) by the treatment was 
significantly different from that of mock treatment (p < 0.05). 
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 CHAPTER 3 - Bile Acids Promote HCV Replication Through the 
EGFR/ERK Pathway in Replicon-Harboring Cells 
Abstract 
 
Hepatitis C virus (HCV) undergoes chronic infections in hepatocytes, which frequently results in 
liver cirrhosis and cancer.  There are currently over 170 million people persistently infected with 
HCV worldwide, and spontaneous clearance of the virus is rare. Recently, we demonstrated that 
bile acids promoted the replication of HCV and compromised the anti-HCV effects of interferon 
alpha (IFN-α) in replicon-harboring cells. To explore a potential mechanism for our observation, 
we studied the effects of bile acids on the epidermal growth factor receptor (EGFR) and the 
extracellular signal regulated kinase (ERK) pathway in association with HCV replication in 
replicon-harboring cells containing either genotype 1a or 1b.  First, we found that various bile 
acids (chenodeoxycholic acid, glycochenodeoxycholic acid, deoxycholic acid and 
ursodeoxycholic acid) significantly increased the expression of a reporter protein through the 
activator protein-1 (AP-1) and serum responding element (SRE), and this was correlated with the 
activation of EGFR and an extended S-phase during cell cycle progression in the presence of bile 
acids. Second, the inhibitors of EGFR (AG1478) or mitogen-activated protein kinase kinase 1/2 
(U0126) significantly mitigated the bile acid-mediated promotion of HCV replication in the 
cells. Finally, when AG1478 or U0126 were added to the treatment of bile acids and IFN-α, they 
were able to restore the anti-HCV effects of IFN-α in replicon-harboring cells. Our data suggest 
that the addition of an EGFR or ERK inhibitor to the current IFN-α based regimen may improve 
overall treatment efficacy by blocking the bile acid-mediated promotion of HCV replication. 
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Introduction 
 
Hepatitis C virus (HCV) is a single-stranded, positive sense RNA virus with a genome length of 
approximately 10 kb (10, 21, 22, 24).  HCV can persist as a chronic infection in hepatocytes, and 
the spontaneous clearance of an HCV infection is rare (24, 27).  Furthermore, chronic HCV 
infections frequently lead to liver cirrhosis and cancer (2, 31).  The current standard treatment for 
chronic HCV infection is a combination therapy consisting of pegylated interferon alpha (IFN)-α 
and ribavirin (13, 29). Both IFN-α and ribavirin have been shown to be cost effective and 
demonstrate significant antiviral effects against a HCV (6, 43, 46).  The combination therapy is 
very effective against HCV genotype 2 and 3 viruses resulting in sustained virological response 
rate of around 80%. However, the effectiveness of the combination treatment is low (40-50%) in 
patients infected with HCV genotype 1 (27).  The lack of an effective treatment for HCV 
genotype 1 serves as a motivation to gain further knowledge of the HCV replication process and 
its relationship with the host cells.   
 
While several HCV strains have recently been isolated that have been successfully tissue culture 
adapted, the majority of HCV remains fastidious in cell culture systems (24, 42, 44, 45, 47). As a 
solution to the lack of tissue culture adapted viruses a cell based virus replication system, 
replicon-harboring cells were established and have provided an excellent tool for the study of 
virus replication and the development of antivirals (4, 25, 40). In our previous study, we 
demonstrated that bile acids promoted HCV replication and compromised the anti-HCV action of 
interferon (IFN)-α using replicon-haboring cells containing HCV genotype 1b (GS4.1 cells) (8). 
Our study suggested that bile acids may be a reason for low efficacy of IFN based treatment in a 
large percentage of patients with chronic HCV infections (8). Various bile acids including 
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chenodeoxycholic acid (CDCA), glycochenodeoxycholic acid (GCDCA), deoxycholic acid 
(DCA), and ursodeoxycholic acid (UDCA) all promoted HCV replication and interfered with 
IFN-α action in the replicon-harboring cells (8). Scholtes et al. (38) also demonstrated that bile 
acids enhanced the replication of genotype 1, but not genotype 2 HCV.  
 
Bile acids have been shown to promote the proliferation of various cells including hepatocytes 
via several pathways including the epidermal growth factor receptor (EGFR) (14, 16-19, 34). It 
has been suggested that the highest levels of HCV RNA and proteins are observed while the 
replicon-harboring cells were undergoing active division (1, 32), suggesting that HCV 
replication may be associated with the cell cycle progress. Therefore, we hypothesized that bile 
acids promote HCV replication in replicon-harboring cells by modulating cell cycle progress via 
the EGFR/extracellular signal regulated kinase (ERK) pathway in replicon-harboring cells.  In 
this report, we found that bile acids led to the activation of the promoter activities of activator 
protein 1 (AP-1) and serum responding element (SRE) in replicon-harboring cells. We also 
demonstrated that bile acids modulated the cell cycle progression by extending S stage, which 
was associated with the phosphorylation of EGFR and enhanced levels of both HCV RNA and 
protein in the cells.  In addition, the inhibitors of either EGFR (AG1478) or the mitogen-
activated protein kinase kinase (MEK) 1/2 (U0126) blocked bile acid-mediated promotion of 
HCV replication in the cells.  Finally, we found that the interference of IFN-α action by bile 
acids was mitigated in the presence of the EGFR or ERK inhibitor. Our data suggest that the 
addition of an EGFR or ERK inhibitor to the current IFN-α based regimen may improve overall 
treatment efficacy by blocking the bile acid-mediated promotion of HCV replication. 
Materials and Methods 
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Cell Lines and Reagents.  
 
Huh-7, GS4.1 (replicon-harboring cells with the HCV 1b genotype, provided by Dr. C. Seeger at 
the Fox Chase Cancer Center, Philadelphia, PA), and 1A7 (replicon-harboring cells with the 
HCV 1a genotype, provided by Dr. S. Lemon at the University of Texas Medical Branch at 
Galveston, Galveston, TX) were maintained in Dulbecco’s Minimum Essential Medium 
(DMEM) containing 10% fetal bovine serum.  Both GS4.1 and 1A7 cells were maintained in the 
presence of G418 (Cellgro, Manassas, VA) at 0.5 μg/ml.  Antibodies against HCV NS5b, β-
actin, phosphor-EFGR or EGFR were obtained from Santa Cruz Biotechnology, Inc. (Santa 
Cruz, CA). Bile acids, chenodeoxycholic acid (CDCA), glycol-chenodeoxycholic acid 
(GCDCA), deoxycholic acid (DCA), and ursodeoxycholic acid (UDCA), were obtained from 
Sigma-Aldrich (St. Louis, MO).  GCDCA was resuspended in deionized-distilled water, while all 
unconjugated bile acids (CDCA, UDCA, and DCA) were resuspended in dimethyl sulfoxide 
(DMSO). IFN-α (recombinant IFN-αA/D human), AG1478 and U0126 were also obtained from 
Sigma-Aldrich. 
The AP-1 and SRE Promoter Assay.  
 
Replicon-harboring cells (GS4.1) were transfected with 2 μg of either pAP1-TA-Luc or pSRE-
TA-Luc (Clonetech, Palo Alto, CA), and 2 μg of pRL-CMV (Promega, Madison, WI) using 
Lipofectamine 2000 (Invitrogen, Carlsbad, CA). After 4 hr of transfection, cells were incubated 
in the fresh media containing CDCA (100 μM), GCDCA (200 μM), DCA (100 μM), UDCA (200 
μM), or a combination of CDCA (100 μM) and U0126 (20 μM).  Cells were further incubated 
for 24 hr before being lysed and subjected to luciferase assay using a Dual Glo luciferase assay 
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kit (Promega). The level of firefly luciferase expression was normalized against the expression 
level of the renilla luciferase encoded for by pRL-CMV. 
Cell Cycle Analysis.  
 
Semi-confluent GS4.1 or 1A7 cells were synchronized using aphidicolin (Sigma-Aldrich) at a 
concentration of 5 μM for 24 hr before being stimulated with CDCA (100 μM), GCDCA (200 
μM), or CDCA (100 μM) + U0126 (20 μM) for 0, 6, 12, and 24 hr.  For cell cycle analysis, cell 
monolayers were lysed with Vindelov’s propidium iodide (PI) solution (35) and cell nuclei were 
strained through a cell strainer cap on 5 ml round bottom tubes (BD Biosciences, San Jose, CA). 
Nuclei were analyzed on a Beckman Dickenson flow cytometer and the cell division stages were 
analyzed using ModFit LT (VSH Software, Topsham, ME).  Dual-staining examining cell cycle 
and the expression of HCV protein was performed on cells with or without the treatment of bile 
acids using the BD Cytofix/Cytoperm kit (BD Biosciences).   Briefly, after each treatment, cells 
were fixed and permeabilized in 200 µl of BD Fixation/Permeabilization solution with a 1:100 
dilution of a mouse monoclonal NS5b antibody (Santa Cruz Biotechnology, Santa Cruz, CA) 
overnight.  Cells were washed 3 times in BD Perm/Wash Buffer and incubated with a FITC-
labelled goat-anti-mouse secondary antibody (Caltag [Invitrogen, Carlsbad, CA]) at a dilution of 
1:100 in Perm/Wash Buffer for 2 hr.  Following incubation, cells were washed 3 times in BD 
Perm/Wash buffer and transferred to either a PI solution or PBS and allowed to sit for 1 hr before 
analysis.  Fifty thousand cells were analyzed on the FACSCalibur (Beckman Dickenson, 
Franklin Lakes, NJ) and NS5b levels were analyzed using the CellQuest (Beckman Dickenson). 
The specific percentage of cells at a particular stage in the cell cycle was determined using 
ModFit LT. 
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 Treatment of Replicon-Harboring Cells with Bile Acids, Inhibitors of EGFR (AG1478) 
or MEK1/2 (U0126), and IFN-α 
 
First, we examined the cytotoxic effects of each bile acid and/or the inhibitor on GS4.1 or 1A7 
cells using a CytoTox 96
®
 non-radioactive cytotoxicity assay kit (Promega, Medison, WI) to 
obtain the concentration of each agent with minimum cell toxicity. To examine the role of EGFR 
and the ERK pathway in bile acid-mediated promotion of HCV replication and/or interference 
with the anti-HCV action of IFN-α, AG1478 and U0126 were added in conjunction with various 
bile acid concentrations. Both GS4.1 and 1A7 cells were used in this study. First, the treatments 
were focused on the ability of EGFR or ERK inhibitors in blocking bile acid-mediated 
enhancement of the HCV replication. The treatments included AG1478 (15 or 30 μM), U0126 
(10 or 20 μM), CDCA (100 μM), and CDCA in combination with AG1478 or U0126, using the 
concentrations listed above (Table 1).  Cells were incubated with the various treatments for 24 hr 
before HCV RNA and protein levels were measured using real-time quantitative reverse 
transcription-PCR (qRT-PCR) and Western blot analysis as described in section 2.5. Second, the 
treatments were designed to examine the ability of the EGFR or ERK inhibitor in restoring the 
anti-HCV effects of IFN-α in the presence of bile acids.  The treatments included AG1478 (15 or 
30 μM), U0126 (10 or 20 μM), IFN-α (5 U/ml), CDCA (100 μM), CDCA + AG1478 or U0126, 
IFN-α + U0126 or AG1478, IFN-α + CDCA, and CDCA + IFN-α + AG1478 or U0126 (Table 
1).  The cells were incubated with the various treatments for 24 hr before HCV RNA and protein 
levels were measured using qRT-PCR and Western blot analysis, respectively.   
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Detection of HCV RNA and NS5b Protein.  
 
The HCV RNA and NS5b protein levels were measured 24 hr after semi-confluent GS4.1 or 1A7 
cells were treated with various bile acids, IFN-α and/or AG1478, and/or U0126 (Table 1) by 
qRT-PCR or western blot analysis, respectively.  Total RNA was isolated from GS4.1 or 1A7 
cells in 6-well plates following treatment using the RNeasy Mini Kit (Qiagen, Valencia, CA) and 
qRT-PCR was performed using a One-Step Superscript III qRT-PCR kit (Invitrogen) with 
primers and probes previously described (8).  Western blot analysis was performed on cells lysed 
with lithium dodecyl sulfate (LDS) sample buffer containing 2% β-mercaptoethanol.  NS5b 
protein was detected using a mouse monoclonal anti-NS5B antibody at a 1:1000 dilution in 2% 
non-fat dry milk (NFDM) followed by a secondary HRP conjugated goat-anti-mouse (Pierce 
Biosciences, Rockford, IL) at 1:1000.  Protein was visualized using a chemiluminescent 
substrate (Pierce Biosciences).  β-actin levels were measured by qRT-PCR and Western blot 
analysis for the normalization of RNA and protein levels of each sample, respectively. The 
expression of NS5B in cells with or without bile acid treatment was also examined by flow 
cytometry analysis as described above.   
Detection of Phosphor-EGFR and EGFR.   
 
The activation of EGFR was detected using Western blot analysis with phosphor-EFGR and 
EGFR antibodies.  Briefly, semiconfluent GS4.1 cells were incubated with CDCA (100 μM), 
GCDCA (200 μM), or UDCA (200 μM) for 30 min before lysis with LDS sample buffer 
containing 2% β-mercaptoethanol.  Western blot analysis was performed using an anti-phosphor-
EGFR or EGFR antibody at 1:1000 dilution in 2% NFDM and a secondary anti-mouse HRP 
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conjugated detection antibody at 1:500. Proteins were visualized using a chemiluminescent 
substrate as described above. 
Statistical Analysis 
 
Each experiment was repeated a minimum of three times.  Statistical analysis was performed 
using GraphPad Prism 5.0 data analysis software. 
Results 
Bile Acids Increased HCV Replication in 1A7 cells.  
 
In a previous study, we demonstrated that bile acids promoted the replication of HCV RNA and 
proteins in GS4.1 cells containing a genotype 1b replicon.  In this report, we found that various 
bile acids also increased the levels of HCV RNA and protein in 1A7 cells containing a genotype 
1a replicon. 1A7 cells were treated with mock-medium, CDCA, GCDCA, or UDCA, and HCV 
RNA or NS5b was measured by real-time qRT-PCR, or Western blot analysis or flow cytometry 
analysis, respectively.  After incubation with 100 μM or 20 μM of CDCA for 24 hr, HCV RNA 
levels in 1A7 cells were significantly increased (p<0.05) to 226% ± 14 or 163% ± 19 compared 
to mock treatment (100%). The levels of HCV RNA were further increased to 312% ± 12 and 
237% ± 13 compared to mock-treatment after a 48 hr incubation. The incubation of cells with  
200 μM GCDCA or 100 μM UDCA also showed an increase in HCV RNA levels to 140% ± 9 or 
185% ± 12 (24 hr) and 166% ± 31 or 206% ± 17 (48 hr)  (p<0.05), respectively.  The protein 
levels of HCV NS5b correlated with HCV RNA levels after the incubation with CDCA 100 µM 
(Figure 3-1B-Lane 2), with a significant enhancement in protein level compared to mock treated 
cells (Figure 3-1B–Lane 1).  Enhanced NS5b protein levels were observed in all other treatments 
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including CDCA 20 µM (Lane 3), GCDCA 200 µM (Lane 4), and GCDCA 100 µM (Lane 5). 
The flow cytometry analysis also confirmed the enhanced expression of NS5b by the treatment 
with bile acids: after treatment with 100 μM of CDCA for 24 hr, cells expressing NS5b had 
increased compared to mock treated cells (47% vs 33%) (Figure 3-1C).   
 
Enhancement of Luciferase Activity Under AP1 or SRE Promoter After Bile Acid 
Treatment in GS4.1 Cells 
   
Luciferase activity under the control of the AP-1 or SRE promoter was significantly increased 
(greater than a 1.8 fold, p<0.05) by the treatment with CDCA (100 μM), DCA (100 μM), 
GCDCA (200 μM), or UDCA (200 μM) for 24 hr compared to mock-medium (negative) 
treatment (Figure 3-2A). CDCA was most efficient among tested bile acids in increasing 
luciferase activity under AP-1 or SRE, which was consistent in promoting HCV replication in 
cells (Figure 1A) (8). The treatment of the cells with U0126 blocked the bile acid-mediated 
enhancement of luciferase activity (Figure 3-2B), which further suggests that bile acids induce 
the activation of the signalling pathways of AP-1 or SRE in the cells.   
 
Bile Acids Induce a Prolonged S Phase Period in Replicon-Harboring Cells 
  
Since AP-1 and SRE are known to play a role in modulation of the cell cycle, we analyzed cell 
cycle progression of GS4.1 and 1A7 cells after treatment with mock-medium, CDCA, GCDCA, 
and U0126 + CDCA for up to 24 hr (Figure 3-3 and Table 3-2). For 1A7 cells, cell cycle 
progression with G1, S, or G2 stages showed no significant difference between mock, CDCA, or 
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GCDCA at 6 hr post treatment (Table 3-2).  However, 1A7 cells in S phase were significantly 
increased (p<0.05) at 12 hr post treatment with CDCA or GCDCA when compared to mock 
treated cells: 86% (CDCA) and 81% (GCDCA) vs 67% (Mock) (Table 2). At 24 hr, 1A7 cells in 
S phase were also significantly increased (p<0.05) by treatment with CDCA compared to mock-
treatment (40% vs 14%) (Table 3-2). For GS4.1 cells, cell cycle progression was similar to 1A7 
cells with or without bile acids for 6 or 12 hr with the treatment with CDCA or GCDCA also 
increased the percentage of cells in S phase at 12 hr (Figure 3-3A). By dual-staining examining 
NS5b positive cells and cell cycle progression with the treatment of mock-medium or CDCA for 
24 hr, both cells at S-stage and cells expressing NS5b increased by CDCA (Figure 3-3B). In the 
presence of U0126 (20 μM), cell cycle progression with CDCA was delayed at 6 hr (Figure 3-
3A).  
 
Bile Acid-Mediated Promotion of HCV Replication is Correlated with EGFR Pathway.   
 
We determined bile acids induced the activation of EGFR in replicon-harboring cells. When 
GS4.1 cells were incubated with medium containing mock-medium, CDCA, UDCA, or GCDCA 
for 30 min, the phosphorylation of EGFR was only evident in cells with bile acids (Figure 3-4). 
To examine the role of an EGFR inhibitor in the bile acid-mediated enhancement of HCV 
replication, semi-confluent GS4.1 or 1A7 cells were incubated with mock-medium, CDCA, 
AG1478 or CDCA + AG1478 for 24 hr, and HCV replication was measured. The treatment with 
AG1478 alone did not change HCV RNA levels in the cells, but when AG1478 was co-treated 
with CDCA (100 μM), it significantly reduced (p<0.05) CDCA-mediated enhancement of HCV 
RNA levels at the concentrations above 15 μM.  The treatment with CDCA increased HCV RNA 
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levels to over 200% compared with the mock-treatment in both GS4.1 and 1A7 cells. However,  
the HCV RNA levels were significantly (p<0.05) decreased to 151% ± 4 or 135% ± 5 in GS4.1 
and 1A7 cells respectivly in the presence of 30 μM of AG1478 (plus CDCA)  (Figure 3-5A). 
Like AG1478, U0126 mitigated bile acid-mediated promotion of HCV replication in GS4.1 or 
1A7 cells, while U1026 (10 or 20 μM) alone did not significantly alter the HCV RNA level 
(Figure 3-5B). While the treatment with CDCA increased HCV RNA levels to over 200%, in the 
presence of U0126 (plus CDCA), the HCV RNA levels were significantly (p<0.05) decreased to 
126% ± 11 or 158% ± 7 (GS4.1) and 109% ± 14 or 175% ± 5  (1A7) at 20 or 10 μM, 
respectively (Figure 3-5B).  The levels of HCV NS5b were well correlated with HCV RNA 
levels after treatment with AG1478 and/or bile acids in replicon-harboring cells (Figure 3-5C).  
 
The Inhibitor of EGFR or ERK Restores the Anti-HCV Action of IFN-α in the 
Presence of Bile Acids.   
 
Because bile acids compromise the anti-HCV action of IFN-α, we examined if AG1478 or 
U0126 could restore IFN-α action in the presence of bile acids.  GS4.1 or 1A7 cells were treated 
with IFN-α alone (5 U/ml), double treatment of IFN-α and CDCA (100 μM) or triple treatment 
of IFN-α, CDCA and AG1478 (30 μM) or U0126 (20 μM). The levels of HCV RNA were 
measured after 24 hr of treatments. In GS4.1 cells the treatment with IFN-α reduced the HCV 
RNA levels to 39% ± 3 of those with mock-treatment; but in the presence of CDCA, it was 
reduced to only 97% ± 8 (p<0.05 compared to IFN-α treatment).  With the triple treatment with 
A1478 or U0126, the HCV RNA levels were 64% ± 8 or 50% ± 10 (p<0.05 compared to double 
treatment of IFN-α and CDCA) of those treated with mock-treatment (Figure 3-6).  We found 
similar results with 1A7 cells. While the treatment with IFN-α (5 U/ml) reduced the HCV RNA 
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levels to 51% ± 4 of those with mock-treatment, with the double treatment of IFN-α and CDCA, 
HCV RNA levels were 102% ± 7. The triple treatment of IFN-α, CDCA and A1478 or U0126 
resulted in the HCV RNA levels to 53% ± 16 or 60% ± 5 of those receiving mock-treatment 
(Figure 6). These results suggest the inhibitor of EGFR or ERK restores the anti-HCV action of 
IFN-α in the presence of bile acids. 
Discussion of Results 
While several putative receptors of HCV, including CD81 (9, 12, 28, 33) and human scavenger 
receptor class B1 (15, 26, 37, 41), are distributed throughout the body, HCV mainly replicates 
within hepatocytes in the liver.  This suggests there are hepatocyte-specific cofactors that 
determine the liver tropism of HCV.  Previously we demonstrated that bile acids, both 
conjugated and unconjugated, can play an important role in the up-regulation of HCV replication 
in replicon-harboring cells.  In the body, most bile acids present as conjugated forms with taurin 
or glycin, and they are collected and stored in the gall bladder at concentrations reaching as high 
as 320 mM before released into the upper small intestine (duodenum) (20). Most of bile acids 
returned to the liver through the enterohepatic circulation via the portal vein where 
concentrations of bile acids can reach up to 80 μM as it passes into the liver (23).  In this report, 
we demonstrated that the activation of the EGFR/ERK pathway may play an important role in 
the bile acid-mediated enhancement of HCV replication.  In 2004, Carloni et al. (7) 
demonstrated that CD81, a putitive receptor for HCV, has the ability to activate the ERK 
pathway. In addition, Brazzoli et al. (5) demonstrated that activation of the ERK pathway by 
CD81 was necessary for specific cellular events required for the replication HCV.  When the 
authors blocked the ERK signalling cascade using the MEK 1/2 inhibitor (U0126), viral 
replication was virtually abolished. Previous studies have shown that bile acids are important in 
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the normal regeneration of the liver (14, 16), and they activate the ERK pathway in primary rat 
hepatocytes with the EGFR receptor (34). The ERK pathway stimulates both AP-1 and the SRE 
through a series of intermediate proteins, including the ternary complex factor (TCF) subfamily 
of proteins (11). In accordance with literature we demonstrated that bile acids activate the ERK 
pathway, and found that bile acids led to the enhanced expression of luciferase under both the 
AP-1 and SRE promoters in replicon-harboring cells (Figure 3-2A). In addition, the total 
luciferase activity was significantly reduced when the replicon-harboring cells were treated with 
100 μM CDCA in combination with 20 μM U0126 (Figure 3-2B).  This suggests that signalling 
though the ERK pathway is induced by bile acids and leads to the activation of both AP-1 and 
SRE.  The AP-1 complex is comprised of components from the jun oncogene (JUN), v-fos FBJ 
murine osteosarcoma viral oncogene homolog (FOS), activating transcription factor (ATF), and 
v-maf musculoaponeorotic fibrosarcoma oncogene homolog (MAF) protein families (39).  FOS 
and JUN are the main proteins in mammalian systems which form AP-1 complexes and regulate 
gene expression.  AP-1 has the ability to be both oncogenic and anti-oncogenic through the 
regulation of different sets of genes, including those involved in cell proliferation (3, 39).   
 
Because both AP-1 and SRE lead to cell proliferation, we examined the cell cycle progression of 
replicon-harboring cells in the presence of bile acids using flow cytometry analysis. It has been 
previously reported that cell cycle progression was important in HCV replication, with the 
highest levels of HCV RNA were observed while cells are actively undergoing division in 
replicon-harboring cells (42).  We observed that upon stimulation with various bile acids, 1A7 
and GS4.1 cells entered into extended S phase (Figure 3-3, Table 3-2), which correlated with the 
enhanced expression levels of HCV RNA and proteins (Figure 3-1A-C).  The cell cycle 
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progression of GCDCA treated cells had a shorter S phase hold than its CDCA counterpart.  This 
shorter S phase hole correlates with the lower overall levels of HCV RNA and protein seen after 
stimulation with bile acids.  The extended S phase that is induced by bile acids may be caused by 
the continuous stimulation of the AP-1 and SRE promoters mediated by the constitutive 
activation of the ERK pathway in the presence of bile acids.  The activation of the ERK pathway 
upon binding of HCV to CD81, and the continuous stimulation by bile acids suggest that the 
ERK pathway may play an important role in the overall life-cycle of HCV.  Furthermore, both 
the HCV core and NS5b proteins have been demonstrated to induce a high percentage of cells to 
hold in S phase when overexpressed in a non-neoplastic human hepatocyte cell line (30, 36), 
suggesting that active replication of HCV may enhance cells in S phase, consequently further 
increase virus replication. However, it is not clear what exact mechanism(s) are involved in 
enhanced virus replication in S staged cells. It is possible that proteins expressed in cells in S 
stage may act as co-factors for virus replicase, and we will examine this possibility in the future.   
When GS4.1 cells were treated with either CDCA, GCDCA, or UDCA, the phosphorylation of 
EGFR was seen in the presence of each bile acid after 30 min (Figure 3-4), suggesting an 
important role of EGFR in AP-1 and SRE activation and the cell cycle progress in the presence 
of bile acids.  A 30 min time point was chosen because previously published data shows high 
levels of EGFR phosphorylation after bile acid stimulation in rat hepatocytes (Rao et al. 2002).  
To study the effect of the activation of the EGFR/ERK pathway on bile acid-mediated 
enhancement of HCV replication and the interference with the anti-HCV effects of IFN-α, we 
used AG1478 and U0126.  While AG1478 alone had little effect on HCV replication, it 
significantly reduced CDCA-mediated promotion of HCV replication at concentrations above 15 
μM in both GS4.1 and 1A7 cells (Figure 3-5A).  Similar to AG1478, U0126 had little effect on 
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the HCV replication alone, but when combined with CDCA it significantly mitigated the bile 
acid-mediated enhancement of HCV (Figure 3-5B).  These data suggest that the ERK pathway is 
playing an important role in the bile acid-mediated enhancement of HCV RNA in replicon-
harboring cells.  Since we previously demonstrated that bile acids compromise the anti-HCV 
action of IFN-α, we hypothesized that AG1478 and/or U0126 can restore the IFN-α action in 
replicon-harboring cells in the presence of bile acids by reducing the overall bile acid-mediated 
enhancement of the HCV replicon. The anti-HCV effects of IFN-α were significantly improved 
when GS4.1 and 1A7 cells were treated with the combination of CDCA and IFN-α with either 
U0126 or AG1478 (Figure 3-6). These data suggest that the addition of an EGFR or ERK 
inhibitor, such as AG1478 or U0126 to the current IFN-α based treatment may improve overall 
efficacy by blocking the bile acid-mediated increase in HCV replication.  In summary, we 
demonstrated that bile acids induce EGFR/ERK pathway in genotype 1a and 1b replicon-
harboring cells, which was associated with increased levels of HCV replication.  Disruption of 
this signalling by either AG1478 or U0126 can significantly reduce the bile acid-mediated 
promotion of HCV and restore the anti-HCV effects of IFN-α in the cells in both genotypes.  
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Table 3-1. List of Treatment of Replicon-Harboring Cells with Bile Acids, Inhibitors of 
EGFR or ERK, and IFN Alone or Together in this Study. 
  
 Treatment                                                     Compounds (concentrations) 
 
Mono-treatment CDCA (100 μM, 20 μM); GCDCA (200 μM, 100 μM); DCA (100 μM); 
 
   UDCA (100 μM); AG1478 (30 μM, 15 μM); U0126 (20 μM, 10 μM); 
 
   IFN-α (5 U/ml) 
 
Dual-treatment   CDCA (100 μM) + IFN-α (5 U/ml); CDCA (20 μM) + IFN-α (5 U/ml); 
 
CDCA (100 μM) + AG1478 (30 μM); CDCA (100 μM) + AG1478(15 
μM); 
 
   CDCA (100 μM) + U0126 (20 μM); CDCA (100 μM) + U0126 (10 μM); 
 
   AG1478 (30 μM) + IFN-α (5 U/ml); U0126 (20 μM) + IFN-α (5 U/ml); 
 
Triple-treatment  AG1478 (30 μM) + CDCA (100 μM) + IFN-α (5 U/ml); 
 
   U0126 (20 μM) + CDCA (100 μM) + IFN-α (5 U/ml); 
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 Table 3-2. Cell Cycle Analysis of 1A7 Cells Incubated with Mock-Medium, CDCA (100 
μM) or GDCDA (200 μM) for 6, 12, or 24 hr.   
Treatment Percentage (%) of cells* 
 0 hr 6 hr 
 G1 S G2 G1 S G2 
Mock 75±3 25±3 0 25±16 75±15 1±1 
CDCA - - - 41±28 59±27 1±1 
GCDCA - - - 24±16 75±16 1±1 
 12 hr 24 hr 
 G1 S G2 G1 S G2 
Mock 10±1 67±10 23±10 67±2 13±3 20±2 
CDCA 9±2 86±6** 6±4 26±4 40±4** 38±3 
GCDCA 8±1 81±1** 11±0 61±4 14±4 25±1 
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Figure 3-1.  Enhancement of HCV Replication After Bile Acid Treatment in 1A7 Cells.   
Semi-confluent cells were treated with mock-medium, CDCA, GCDCA, or UDCA for 24 or 48 
hr. HCV RNA (A) or NS5b (B) was measured by real-time qRT-PCR or Western blot analysis, 
respectively. A. qRT-PCR levels after treatment with mock-medium, CDCA 100 μM 
(CDCA100), CDCA 20 μM (CDCA20), GCDCA 200 μM (GCDCA200), GCDCA 100 μM 
(GCDCA100) and UDCA 200 μM (UDCA200) for 24 or 48 hr. Asterisk (*) indicates that the 
RNA levels by the treatment were significantly increased compared to those by control (mock-
medium) treatment (p<0.05). B. Western blot analysis detecting NS5b after the treatment for 24 
hr. Upper panel, lane 1: mock-medium; lane 2: CDCA (100 μM); lane 3: CDCA (20 μM); lane 4: 
GCDCA (200 μM); lane 5: GCDCA (100 μM). Lower panel, as a loading control, Western blot 
analysis of β-actin was performed with the same samples. C) Flow cytometry analysis of NS5b 
levels in 1A7 cells with the treatment of mock-medium or CDCA (100 μM) for 24 hr. Staining 
control was prepared the same procedure without the incubation with the NS5b antibody. 
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Figure 3-2. Enhancement of Luciferase Activity Under AP1 or SRE Promoter Control 
After Bile Acid Treatment in GS4.1 Cells. 
The luciferase based plasmid under AP-1 or SRE promoter control was transfected into 
semiconfluent GS4.1 cells. The cells were treated with CDCA 100μM (CDCA100), DCA 
100μM (DCA200), GCDCA 200μM (GCDCA200), UDCA 200μM (UDCA200), or CDCA100 + 
U0126 20μM (U20) 4 hr after transfection and incubated for an additional 24 hr. Asterisk (*) 
indicates that the luciferase activities by the treatment were significantly increased compared to 
those by the control treatment (p<0.05). A). Treatment of various bile acids in the luciferase 
activity under the control of signalling pathways, AP-1 or SRE. B). The effects of U0126 on 
CDCA-mediated induction of luciferase expression under AP-1 or SRE.  Asterisk (*) indicates 
that the luciferase activities by co-treatment with CDCA and U0126 were significantly reduced 
compared to those by the treatment with CDCA alone (p<0.05). 
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Figure 3-3 Cell Cycle Analysis of GS4.1 Cells After Treatment with Mock, CDCA, 
GCDCA, and U0126 + CDCA. 
Semi-confluent GS4.1 cells were synchronized with aphidicolin at 5 μM for 24 hr before the 
treatment. Cells were treated with mock-medium, CDCA 100 μM (CDCA100), GCDCA 200 μM 
(GCDCA200), or CDCA100 + U0126 20 μM (U20) for 6 or 12 hr before being analyzed for cell 
cycle progression. A. Cells treated with CDCA 100 μM or GCDCA200 μM for up to 12 hr. B) 
Dual-staining examining cell cycle and the expression of HCV protein (NS5b).  Cells were 
treated with mock-medium or CDCA 100 μM (CDCA100) for 24 hr. 
 
 110
0 h
6 h
12 h
Mock CDCA 100 uM GCDCA 200 uM
G1: 77%
S: 23%
G1: 9%
S: 90%
G2: 1%
G1: 13%
S: 86%
G2: 1%
G1: 8%
S: 91%
G2: 1%
G1: 10%
S: 57%
G2: 33%
G1: 11%
S: 80%
G2: 9%
G1: 9%
S: 80%
G2: 11%
CDCA + U0126, 6 h CDCA + U0126, 12 h
G1: 87%
S: 7%
G2: 6%
G1: 11%
S: 86%
G2: 3%
FL2-A
30%
G1: 29%
G2: 39%
S:32%
A
B
Mock
CDCA100
G1: 21%
G2: 53%
S:25%
14%
C
el
l C
ou
nt
FL2-A
C
el
l C
ou
nt
 111
Figure 3-4. The Activation of EGFR by the Treatment with Bile Acids in GS4.1 cells. 
Confluent GS4.1 cells were treated with mock-medium, CDCA, GCDCA, or UDCA for 30 min, 
and then cell lysates were prepared and Western blot analysis detecting phosphor-EGFR or 
EGFR.  Lane 1: parental Huh7 cells with mock-treatment; lane 2: mock-treatment; lane 3: 
CDCA 100 μM; lane 4: GCDCA 200 μM; lane 5: UDCA 200 μM. 
1            2          3           4           5
P-EGFR
EGFR
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Figure 3-5. Inhibitors of EGFR or ERK in Bile Acid-Mediated Promotion of HCV 
Replication. 
Semi-confluent GS4.1 or 1A7 cells were incubated with mock-medium, CDCA, AG1478 or 
CDCA + AG1478 for 24 hr, and HCV replication was measured by detecting HCV RNA (A and 
B) or protein (C). A. Real time qRT-PCR analysis of HCV RNA levels after the treatment with 
CDCA 100 μM (CDCA100), AG1478 30 μM (AG30), CDCA100 + AG30, or CDCA100 + 
AG1478 15 μM (AG15).  B. Real time qRT-PCR analysis of HCV RNA levels after the 
treatment with CDCA100, U0126 20 μM (U20), CDCA100 + U20, or CDCA100 + U0126 10 
μM (U10). Asterisk (*) indicates that the RNA levels by double treatment with CDCA and 
AG1478 or U0126 were significantly reduced compared to those by the treatment with CDCA 
alone (p<0.05).  C. Western blot analysis of HCV protein NS5B in GS4.1 cells after treatment 
with CDCA, AG1478 or CDCA + AG1478.  Lane 1: Mock, Lane 2: CDCA 100 μM, Lane 3: 
AG1478 30 μM + CDCA 100 μM, Lane 4: AG1478 5 μM + CDCA 100 μM, and Lane 5: 
AG1478 30 μM.  As a loading control, Western blot analysis of β-actin was performed with the 
same samples.   
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Figure 3-6. Inhibitors of EGFR or ERK in Anti-HCV Action of IFN in the Presence of 
CDCA. 
HCV RNA levels were measured after 24 hr treatments with IFN 5 U/ml (IFN5), CDCA 100 μM 
(CDCA100) + IFN5, or CDCA100 + IFN5 + (AG1478 30 μM [AG30] or U0126 20 μM [U20]).  
Asterisk (*) indicates that the RNA levels by IFN 5 U/ml treatment were significantly reduced 
compared to those by mock-treatment (p<0.05). Double asterisk (**) indicates that the RNA 
levels by triple treatment were significantly reduced compared to those by double treatments of 
IFN5 + CDCA100 (p<0.05).  
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CHAPTER 4 - The Limitation of Antiviral Effects Against HCV Due 
to Bile Acids 
Abstract 
 
Hepatitis C Virus (HCV) currently poses a significant health problem with the WHO reporting 
over 170 million infected patients worldwide, with an estimated 3 to 4 million new infections 
occurring each year.  With HCV accounting for almost 66% of the liver transplants in the United 
States it is a disease that draws considerable attention. There are 6 recognized genotypes of HCV 
worldwide, with genotypes 1 and 2 being of major concern in the United States.  Currently, the 
standard treatment for chronic HCV infections is a combination of interferon (IFN) and ribavirin, 
but around half of patients infected with HCV genotype 1 fail to show a sustained virologic 
response to the treatment and remain chronically infected.  We previously demonstrated that bile 
acids compromise the anti-HCV effects of IFN. It has been shown that 17AAG (17-
[Allylamino]-17-demethoxygeldanamycin), cyclosporine A, and ribavirin could reduce the 
replication of HCV in replicon-harboring cells. In this study, we examined the effects bile acids 
on anti-HCV activity of these agents in mono- or combined treatment with IFN in replicon-
harboring cells containing either genotype 1A or 1B. First, we found that bile acids also 
compromised the anti-HCV action of each agent. Bile acids either partially or completely 
blocked the anti-HCV action of 17AAG, cyclosporine A, or ribavirin in the cells. When we 
examined the effects of bile acids on the combined treatments of each agent with IFN, it 
significantly restored the anti-HCV activity of each agent with varying degrees. With or without 
bile acids, 17AAG or cyclosporine A have significantly higher efficiency than ribavirin in mono- 
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or combined therapy.  These results suggest the importance of combination therapies to increase 
the overall sustained virological response in HCV patients. 
Introduction 
 
HCV poses a significant global health problem.  The World Health Organization (WHO) 
estimates that there are approximately 170 million infected individuals worldwide with an 
additional 3 to 4 million additional infections occurring yearly, resulting in close to 3% of the 
world’s population being chronically infected with HCV (1).  Of the 3 to 4 million new 
infections occurring each year only 25% of these are symptomatic infections.  Unfortunately, out 
of these 25%, 60% to 80% will develop chronic liver disease with approximately 20% of those 
patients progressing to liver cirrhosis.  HCV is one of the leading causes of liver cancer, causing 
between 50% to 76% of all liver cancer cases and accounting for almost 66% of all liver 
transplants. 
 
The Hepatitis C Virus (HCV) is a member of the Flaviviridae family of viruses along with 
Yellow Fever Virus, West Nile Virus, Dengue Fever Virus, and classical swine fever viruses.  
The HCV genome is a 9.6-kb positive sense, single stranded RNA genome that encodes at least 
10 individual proteins (9, 19, 20, 23).  The 10 individual proteins are encoded into one large 
poly-protein that’s composed of approximately 3000 amino acids.  This poly-protein is further 
cleaved by the NS3-4A serine proteases into the 10 individual proteins (9).  HCV displays a liver 
tropism that is not completely understood.  The primary receptor for HCV is thought to be CD81 
which is found throughout the body eliminating it as a possible reason for liver tropism (7, 13, 
28, 31).  A second line of reasoning deals with liver specific cofactors that may be required for 
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HCV replication.  Chang et al (2004) described the relationship between porcine enteric 
calicivirus (PEC) and bile acids. Originally PEC was fastidious in tissue culture, it was later 
determined though that addition of bile acids allowed PEC to actively replicate in cell culture (5).  
If the replication of HCV is similar, it may also require a liver specific cofactor to actively 
replicate. Within the past few years multiple genotypes of HCV have been isolated, and 
successfully tissue culture adapted.  Although the majority of strains remain fastidious in cell 
culture, there now exist representative virus strains from both genotypes 1 and 2 (23, 39, 44, 45, 
47).  Replicon-harboring cells containing either the nonstructural genes or the full length HCV 
genome were established to enhance the our ability to design antivirals and better understand the 
HCV replication cycles in the absence of tissue culture adapted viruses.  These systems are 
currently available in a wide variety of genotypes providing an excellent base for the screening 
of multiple antiviral drugs across the spectrum of HCV genotypes (2, 24, 37). 
 
Currently, the accepted treatment for chronic HCV infections involves a combination therapy 
consisting of high dose pegylated interferon (IFN)-α and Ribavirin (3, 42, 46).   Both 
individually and in combination IFN-α and Ribavirin have been shown to be an effective 
treatment for against HCV viruses from within genotypes 2 and 3.  Genotype 2 and 3 viruses 
have a sustained virological response rate of over 80% after treatment.  Unfortunately, HCV 
viruses that are members of genotype 1 have a much lower response rate to the combination 
treatment, with sustained virological responses dropping as low as 40 to 50% (26). 
Unfortunately, the exact mechanisms that underlie the large number of genotype one non-
responders are not completely understood.  Over the years a number of antivirals including 
Cyclosporine A and 17-AAG have been looked at for their anti-HCV activity (18, 30, 38, 41).  
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These antivirals have been demonstrated to have significant antiviral effects on HCV replication 
either in vitro or in vivo.  Numerous attempts have being made to identify new antiviral 
compounds that specifically target either viral proteins or cellular proteins that are required for 
the viral lifecycle.  Currently, the majority of the antiviral development for HCV is targeted 
towards the NS3-4 serine protease and NS5B RNA-dependent RNA polymerase (10, 22).  While 
targeting these proteins is highly effective in disrupting the viral lifecycle there are difficulties 
with this approach.  Viral targeted antivirals for HCV have to be able to cope with the rapid 
mutation rates of the HCV genome which frequently leads to resistant mutants (33).  The second 
alternative is the development of antivirals targeting various host factors that are required for the 
viral replication cycle.  Due to the fact that these targets display a much slower rate of evolution 
there is a lower probability that you will see resistant mutants rapidly developing to counter the 
antivirals (32).   
 
In our previous study, we demonstrated that bile acids promoted HCV replication and 
compromised the anti-HCV action of IFN-α using replicon-haboring cells containing HCV 
genotype 1b (GS4.1 cells) (4). Our study suggested that bile acids may be a reason for low 
efficacy of IFN based treatment in a large percentage of patients with chronic HCV infections 
(4). Various bile acids including chenodeoxycholic acid (CDCA), glycochenodeoxycholic acid 
(GCDCA), deoxycholic acid (DCA), and ursodeoxycholic acid (UDCA) all promoted HCV 
replication and interfered with IFN-α action in the replicon-harboring cells (4). Scholtes et al. 
(34) also demonstrated that bile acids enhanced the replication of genotype 1, but not genotype 2 
HCV.   They further demonstrated that the enhancement is tied to FXR.  Recent research has 
shown that the epidermal growth factor receptor EGFR inhibitor AG1478 and mitogen-activated 
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protein kinase kinase MEK inhibitor U0126 have the ability to partially restore the IFN action 
even in the presence of bile acids (Patton et al. Submitted).  Therefore, we hypothesized that bile 
acids may disrupt the overall antiviral effectiveness of multiple mono-therapies. 
 
In this report, we demonstrate that bile acids can significantly reduce the effectiveness of 
Ribavirin, 17-AAG, and Cyclosporine A when used a mono-therapies against HCV.  When 
Ribavirin was directly compared to 17-AAG or cyclosporine A, Ribavirin demonstrated 
significantly lower antiviral activity against HCV in vitro in the presence of bile acids.  Further, 
we showed that bile acids can partially disrupt the dual therapies with IFN and each antiviral 
although the overall levels of HCV RNA and protein are well below mock treatment levels with 
the dual therapy in the presence of CDCA. 
Materials and Methods 
Cell Lines and Reagents.  
 
GS4.1 (replicon-harboring cells with the HCV 1b genotype, provided by Dr. C. Seeger at the Fox 
Chase Cancer Center, Philadelphia, PA), was maintained in Dulbecco’s Minimum Essential 
Medium (DMEM) containing 10% fetal bovine serum and 0.5 μg/ml concentrations of G418 
(Cellgro, Manassas, VA).  Antibodies against HCV NS5b and β-actin were obtained from Santa 
Cruz Biotechnology, Inc. (Santa Cruz, CA). Chenodeoxycholic acid (CDCA), 17-(Allylamino)-
17-demethoxygeldanamycin (17-AAG), Cyclosporine A, Ribavirin, and IFN-α (recombinant 
IFN-α A/D human) were obtained from Sigma-Aldrich (St. Louis, MO).  CDCA, 17-AAG, and 
cyclosporine A were resuspended in dimethyl sulfoxide (DMSO).  IFN-α and Ribavirin were 
suspended and diluted in ddH2O. 
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 Treatment of Replicon-Harboring Cells with Bile Acids, Antivirals, and IFN-α.  
 
First, we examined the cytotoxic effects of each bile acid and/or the inhibitor on GS4.1 or 1A7 
cells using a CytoTox 96
®
 non-radioactive cytotoxicity assay kit (Promega, Madison, WI) to 
obtain the concentration of each agent with minimum cell toxicity.  To examine the antiviral 
benefits of each compound GS4.1 replicon-harboring cells were treated for 24 hr with varying 
concentrations of Ribavirin (80 or 40 µM), 17-AAG (0.5 or 0.2 µM), or cyclosporine A (1 or 0.5 
µM) for 24 hr.   Next the GS4.1 cells were treated with each antiviral at the above concentrations 
in the presence of 100 µM CDCA for 24 hr.  Finally, each compound was evaluated as a 
combination therapy with IFN-α (5U/ml) both with and without CDCA (100 µM).  After 24 hr of 
treatment each sample was measured for HCV RNA and protein levels using real-time 
quantitative reverse transcription-PCR (qRT-PCR) and western blot analysis as described below. 
 
Detection of HCV RNA and NS5b Protein.  
 
The HCV RNA and NS5b protein levels were measured 24 hr after semi-confluent GS4.1 were 
treated with CDCA, IFN-α and/or CDCA, and/or one of the antiviral compounds (17-AAG, 
Cyclosporine A, Ribavirin) by qRT-PCR or western blot analysis, respectively.  RNeasy Mini 
Kit (Qiagen, Valencia, CA) was used to isolate total RNA was from GS4.1 cells in 6-well plates 
following treatment.  After the isolation of the total RNA qRT-PCR was performed using a One-
Step Superscript III qRT-PCR kit (Invitrogen) with primers and probes previously described 
(Chang and George, 2007).  Western blot analysis was performed on cells lysed with lithium 
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dodecyl sulfate (LDS) sample buffer containing 2% β-mercaptoethanol.  NS5b protein was 
detected using a mouse monoclonal anti-NS5B antibody at a 1:1000 dilution in 2% non-fat dry 
milk (NFDM) followed by a secondary HRP conjugated goat-anti-mouse (Pierce Biosciences, 
Rockford, IL) at 1:1000.  Protein was visualized using a chemiluminescent substrate (Pierce 
Biosciences).  β-actin levels were measured by qRT-PCR and Western blot analysis for the 
normalization of RNA and protein levels of each sample, respectively. 
Statistical Analysis.   
 
All experiments were repeated a minimum of three separate times.  Statistical analysis was 
performed using GraphPad Prism 5.0. 
Results 
Bile Acids Significantly Impaired Mono-Therapy Ttreatments Consisting of Ribavirin, 
17-AAG, and Cyclosporine A.   
 
In agreement with previous literature we determined that each of the mono-therapies 
significantly reduced the overall levels of HCV RNA when compared to mock treated cells 
(Figure 4-1).  Further we demonstrated that bile acids significantly reduced the effectiveness of 
each of the mono-therapies.  Ribavirin reduced the RNA level to 53% ± 8% at a concentration of 
80 µM and did not significantly reduce the RNA levels at 40 µM (p<0.05) (Figure 4-1A).  In the 
presence of 100 µM CDCA the effectiveness of Ribavirin was significantly decreased to 132% ± 
24% or 187% ± 41% of mock respectively (p<0.05) (Figure 4-2A).  Replicon-harboring cells 
treated with 5U of IFN-α for 24 hr had HCV RNA level of 66% ± 6% when compared to mock 
treated cells.  In the presence of 100 µM of CDCA the 5U of IFN-α did not significantly reduce 
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the HCV RNA level, 97% ± 8% (p<0.05), when compared to mock treated cells (Patton et al, 
Submitted). The antiviral 17-AAG reduced the HCV RNA level to 52% ± 12% of mock at 0.5 
µM or 75% ± 13% of mock at 0.2 µM concentrations (p<0.05) (Figure 4-1B).  When the cells 
were treated with 100 µM CDCA and 17-AAG the HCV RNA levels significantly increased to 
93% ± 9% or 133% ± 9% respectively (Figure 4-2B) (p<0.05).  Cyclosporine A reduced the 
RNA levels to 48% ± 5% using a concentration of 1 µM and 69% ± 8% at a concentration of 0.5 
µM (Figure 4-1C).  Similar to 17-AAG, when GS4.1 cells were treated in combination with 100 
µM CDCA there was a significant decrease in the effectiveness of the cyclosporine A treatment.  
Replicon-harboring cells treated with a concentration of 1 µM or 0.5 µM of Cyclosporine A and 
100 µM of CDCA showed significant increases in the HCV RNA levels from 48% ± 4% or 69% 
± 8% after mono-therapy to 78% ± 13% and 135% ± 9% respectively after a 24 hr incubation 
period (p<0.05) (Figure 4-2C).  Western blot analysis further supported the qRT-PCR results 
demonstrating that the HCV NS5b protein levels correlated well with the HCV RNA level in the 
replicon-harboring cells for each of the tested antiviral (Figure 4-3A-C). 
 
The Bile Acid Mediated Interference in the Anti-HCV Activity of Each Mono-Therapy 
Can be Partially Mitigated Using Dual Treatments of Ribavirin, 17-AAG, or 
Cyclosporine A in Combination with IFN-α.   
 
To examine the role of each antiviral compound and its ability to reduce the viral load in the 
presence of IFN and CDCA each of the 3 antiviral compounds were added in combination with 
CDCA and IFN-α.  The HCV RNA levels of GS4.1 cells treated with a combination therapy 
consisting of 80 µM or 40 µM  of Ribavirin, 100 µM of CDCA, and 5U of IFN were 73% ± 2% 
or 82% ± 6% respectively(p<0.05).  The 80 µM dose of Ribavirin significantly decreased the 
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HCV RNA levels when compared with the combination therapy of CDCA and IFN alone (Figure 
4-2A).   The combination treatments consisting of 17-AAG at 0.5 µM or 0.2 µM resulted 
significantly decreased RNA levels of 55% ± 3% and 65% ± 2% respectively(p<0.05) (Figure 4-
2B).  The triple therapy incorporating Cyclosporine A also resulted in significant decreases of 
HCV RNA levels, 50% ± 3% or 63% ± 5%, at concentrations of 1 µM or 0.5 µM (p<0.05) 
(Figure 4-2C).  
Discussion 
 
Hepatitis C Virus has a liver specific tropism that is not completely understood.    In our 
previously published work we demonstrate that bile acids, both conjugated and unconjugated, 
can play a role in the up-regulation of HCV RNA and protein levels in both GS4.1 and 1A7 cells 
(4).  We further showed that bile acids have the ability to interfere with the anti-viral activity of 
IFN-α in a dose dependant manner (4).  HCV resides and replicates in the liver where bile acid 
levels can reach up to 80 μM (21), we have previously suggested that this may play a role in the 
many genotype one patients who do not respond to IFN-α treatment (4).  Here we tested the 
ability of bile acids to reduce antiviral effectiveness of 3 different antiviral compounds that 
interact either with the host system or interfere with viral replication.  Scholtes et al. (34) has 
shown that the enhancement of HCV by bile acids occurs through the activation of FXR.  The 
bile acids enhancement of HCV through FXR may indirectly cause a decrease in the antiviral 
efficacy of multiple mono-therapies (34).  We showed that bile acids significantly interfere with 
multiple mono-therapies we propose the addition of a separate compound to the current 
treatment regime may significantly increase the effectiveness of the current IFN-α and Ribavirin 
therapy improving the number of patients exhibiting a sustained virological response. 
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 Ribavirin is an anti-viral drug that is used to treat multiple viral infections including HCV, 
Human immunodeficiency virus (HIV), and severe respiratory syncytial virus RSV infections 
(14, 16, 36).  Once Ribavirin has been metabolized the altered chemical structures resembles that 
of a purine molecule.  This has lead some to suggest that its mechanism of action may revolves 
around inducing rapid and terminal mutations after its incorporation in to the replicating viral 
genome (8).  Unfortunately, the mechanism of actions has yet to be conclusively demonstrated 
and multiple proposed mechanisms exist (11).  In a recent clinical study patients with genotype 1 
demonstrated a 16% higher sustained virological response when given a combination of IFN-α 
and Ribavirin, as opposed to IFN-α alone (15).  In agreement with literature, as a mono-therapy 
Ribavirin was able to significantly reduce the HCV RNA levels to 53% when compared to mock 
treated cells at a concentration of 80 µM although no significant reduction could be seen at 40 
µM.  In the presence of CDCA Ribavirin was unable to reduce the overall HCV load to below 
the mock level (132% ± 24%) although there was a significant reduction from CDCA treated 
cells at 80 µM (Figure 4-1A).  This finding is similar to the CDCA mediated interference with 
IFN-α activity that was reported by Chang et al (2008).  This suggests that the enhancement of 
the HCV RNA and protein levels after treatment with CDCA are greater than Ribavirin alone 
can overcome.  As a possible solution to this problem we looked at the ability of CDCA to 
reduce the effectiveness of a dual treatment with IFN-α and Ribavirin.  This reduction in 
antiviral effectiveness was also noted after the addition of CDCA (100 µM) to a dual treatment 
of Ribavirin (80 µM) and IFN-α (5U / ml), although there was still a significant reduction in the 
overall HCV RNA levels when compared to mock treated cells [(46% ± 2%, 57% ± 2% (without 
CDCA) or 73% ± 2%, 82% ± 6% (with CDCA)) 80 µM and 40 µM respectively] (Figure 4-2A).  
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One of the current draw backs to the treatment of HCV patients with Ribavirin is the high drug 
concentrations that are necessary to have any significant effect of the replication of HCV.  At 
high concentrations the primary side effect of Ribavirin is haemolytic anemia, which has been 
reported in 13% of all clinical trials.   
 
Cyclosporine A is an immunosuppressive drug that is known to have anti-HCV effects .  It has 
been demonstrated to bind to group B cyclophilins which are required by the HCV replicase 
complex for viral replication.  Cyclosporine D, a non-immunosuppressive variant of A appears 
that appears to have similar abilities to inhibit the replication of HCV by binding to types B 
cyclophilins (29, 30).  Currently, a variety of cyclosporine derivatives are being tested as 
candidate antiviral HCV drugs, with the major benefit of many of these derivatives being their 
non-immunosuppressive nature.  Three of these derivatives Debio-025, NIM811, and 
Valisporivir have both shown some promising advances in the developments of anti-HCV drugs 
that target the host system and are in phase III clinical trials (6, 25, 40).  Cyclosporine A has 
been studied extensively as an HCV antiviral and been shown both in vitro and in vivo to have 
strong anti-HCV effects.  As a mono-therapy Cyclosporine A proved effective at a low 
concentration, 1 µM and below, at significantly reducing the HCV RNA levels (Figure 4-1B).  
When cells were treated with a combination of CDCA 100 µM and Cyclosporine A there was a 
significant increase in HCV RNA levels when compared to the mono-therapy alone [48% ± 4%, 
69% ± 8% (without CDCA) or 78% ± 13%, 135% ± 9%(with CDCA)) 1 µM and 0.5 µM 
respectively] (Figure 4-1B).  Unlike Ribavirin and CDCA treated cells, at 1 µM there was still a 
reduction after CDCA treatment when compared to mock treated cells.  When CDCA was added 
to the dual treatment consisting of Cyclosporine A and IFN-α there was a slight reduction in the 
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overall effectiveness of the dual therapy, but a significant reduction over the mock treated cells 
was still shown [(34% ± 4%, 52% ± 2% (without CDCA) or 50% ± 3%, 63% ± 5% (with 
CDCA)) 1 µM and 0.5 µM respectively] (Figure 4-2B).  Cyclosporine A has been used in 
multiple clinical trials as an antiviral treatment for HCV, but due to the immunosuppressive 
properties of the molecule it has not been added to any of the current treatment regimes (12).  
Many of the current derivatives including Debio-025 and NIM-811 may significantly enhance 
the overall effectiveness of the standards treatment practices.  These derivatives have the anti-
HCV properties of cyclosporine A but lack its immunosuppressive properties that make it 
problematic for use in the treatment of patients.  
 
17-AAG a derivative of geldanamycin is a potent HSP90 inhibitor (17, 27, 35).  The 
geldanamycin family was originally isolated as an antibiotic and display weak antibiotic 
properties.  17-AAG is currently being actively studies for the treatment of multiple types of 
cancer due to its ability to inhibit HSP90 which results in the breakdown of specific cellular 
proteins that may cause the death of multiple types of cancer cells (43).  In January of 2009 
Ujino et al. (38) published a paper demonstrating that the ability of 17-AAG to inhibit HSP90 
also lead to the degradation of NS3, an HCV protein that directly interacts with HSP90.  The 
degradation of NS3 occurred in a dose dependent manner and led to the suppression of HCV 
replication (38).  Our results further confirm the ability of low doses of 17-AAG, 0.5 µM and 0.2 
µM, significantly reduce the HCV RNA levels in replicon-harboring cells (Figure 4-1C).  To 
further elicit the effects of bile acids on HCV replication in the presence of the antiviral 17-AAG 
we treated GS4.1 cells with 100 µM CDCA and either 0.5 µM and 0.2 µM 17-AAG.  The results 
closely mirrored that of the dual treatment with CDCA and cyclosporine A.  At a concentration 
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of 0.5 µM the addition of CDCA decreased the effectiveness of 17-AAG by 41% when both 
treatments are normalized to mock.  The interference by bile acids was additionally seen after 
CDCA was added to the combination treatment of IFN-α and 17-AAG.  Although similar to 
cyclosporine A there was still a significant reduction in the HCV RNA and protein levels after 
the combination treatment when compared to mock treatments [(28% ± 3%, 50% ± 8% (without 
CDCA) or 55% ± 3%, 65% ±2% (with CDCA)) 0.5 µM and 0.2 µM respectively] (Figure 4-2C). 
These data suggest that bile acids have the ability to interfere with the anti-HCV activity of 
multiple different antivirals, and the mechanism of action of the antiviral whether cell based or 
viral based plays no role in its depressed antiviral activity.  This suggests that the over-
enhancement of HCV levels by bile acids through FXR may overcome the maximum safe dose 
of antivirals when used as a mono-therapy.  Although the bile acids still effect the dual therapies, 
these therapies still significantly reduce the HCV RNA and protein levels.  The combination 
therapy consisting of IFN-α and Ribavirin is already the standard treatment.  Here we describe 
the effects of bile acids on two other antivirals cyclosporine A and 17-AAG.  Both of these 
antivirals provide a significant reduction in HCV levels, and a greater antiviral effect in the 
presence of bile acids than the current treatment choice Ribavirin.  In the presence of CDCA the 
HCV RNA levels in Ribavirin treated cells were elevated above the mock control.  Both 17-
AAG and cyclosporine A still showed reduced HCV RNA levels in the presence of CDCA.  The 
addition of one or the other of these final two compounds that have been shown to display 
antiviral activity could improve the current IFN-α based treatments for HCV with the hopes of 
increasing the number of patients with a genotype 1 virus that exhibit a sustained virological 
response.  Our reasoning behind this is the ability of both 17-AAG and cyclosporine A to still 
achieve sub-mock HCV RNA levels even in the presence of CDCA.   
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 The current treatment standard consisting of a combination of Ribavirin and IFN-α has been 
shown to be effective at improving the number of patients exhibiting a sustained virological 
response.  Unfortunately, Ribavirin was one of the poorest performing antiviral compounds in 
the study, requiring the highest does and only displaying a limited improvement in HCV RNA 
and protein levels in the presence of CDCA.  Both 17-AAG and cyclosporine A showed 
significantly better reductions of both HCV RNA and protein levels the presence of bile acids.  
In summary, we demonstrate that bile acids have the ability to reduce the anti-HCV effects of 
Ribavirin, 17-AAG, and Cyclosporine when used as a mono-therapy.  Further, either 17-AAG or 
Cyclosporine A offered the best combination treatment with IFN-α for HCV reduction in the 
presence of bile acids. 
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Figure 4-1 Reduction of the HCV RNA Levels in GS4.1 Replicon-Harboring Cells After 
Treatment with Each Antiviral Compound. 
Semi-confluent GS4.1 cells were treated with mock-medium, CDCA, 17-AAG, Cyclosporine A, 
or Lapatinib for 24 hr before the HCV RNA levels were measured by qRT-PCR. A) qRT-PCR 
levels after treatment with mock-medium, CDCA, IFN, Ribavirin 80 µM (Ribavirin 80), 
Ribavirin 40 µM (Ribavirin 40), Ribavirin 80 and CDCA, or Ribavirin 40 and CDCA for 24 hr. 
B) qRT-PCR levels after the treatment with mock medium, CDCA, IFN, 17-AAG 0.5 µM (17-
AAG 0.5), 17-AAG 0.2 µM (17-AAG 0.2), 17-AAG 0.5 and CDCA, or 17-AAG 0.2 and CDCA 
for 24 hr. C) qRT-PCR levels after treatment with mock-medium, CDCA 100 µM (CDCA), IFN-
α 5U (IFN), Cyclosporine A 1 µM (Cyclo 1),  Cyclosporine A 0.5 µM (Cyclo 0.5), Cyclo 1 and 
CDCA, or Cyclo 0.5 and CDCA for 24 hr. Asterisk (*) indicates that the RNA levels by the 
treatment were significantly increased compared to those by control (mock-medium) treatment 
(p<0.05). 
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Figure 4-2. Enhancement in the Antiviral Activity of IFN-α in the Presence of CDCA when 
Combined with a Second Antiviral. 
Semi-confluent GS4.1 replicon-harboring cells were treated with mock-medium, CDCA, IFN, 
CDCA+IFN, or CDCA and IFN and either Ribavirin, 17-AAG, Cyclosporine A, or Lapatinib. A) 
Real time qRT-PCR analysis of HCV RNA levels after treatment with CDCA 100 μM (CDCA), 
Ribavirin 80 μM (Ribavirin 80), Ribavirin 40 μM (Ribavirin 40), IFN-α 5U (IFN), CDCA and 
Ribavirin 80, CDCA and Ribavirin 40, Ribavirin 80 and IFN, Ribavirin 40 and IFN, Ribavirin 80 
and IFN and CDCA, Ribavirin 40 and IFN and CDCA for 24 hr. B) Real time qRT-PCR analysis 
of HCV RNA levels after treatment with CDCA 100 μM (CDCA), 17-AAG 0.5 μM (17-
AAG0.5), 17-AAG 0.2 μM (17-AAG0.2), IFN-α 5U (IFN), CDCA and 17-AAG0.5, CDCA and 
17-AAG0.2, 17-AAG0.5 and IFN, 17-AAG0.2 and IFN, 17-AAG0.5 and IFN and CDCA, 17-
AAG0.2 and IFN and CDCA for 24 hr. C) Real time qRT-PCR analysis of HCV RNA levels 
after treatment with CDCA 100 μM (CDCA), Cyclosporine A 1 μM (Cyclo1), Cyclosporine A 
0.5 μM (Cyclo0.5), IFN-α 5U (IFN), CDCA and Cyclo1, CDCA and Cyclo0.5, Cyclo1 and IFN, 
Cyclo0.5 and IFN, Cyclo1 and IFN and CDCA, Cyclo0.5 and IFN and CDCA for 24 hr. Asterisk 
(*) indicates that the RNA levels by the treatment were significantly increased compared to those 
by control (mock-medium) treatment (p<0.05). 
 137
%
 T
ot
al
 R
N
A
 L
ev
el
%
 T
ot
al
 R
N
A
 L
ev
el
%
 T
ot
al
 R
N
A
 L
ev
el
Antiviral
A
B
C
0%
20%
40%
60%
80%
100%
120%
Mock Ribivarin 80 Ribivarin 40
Antiviral
Antiviral + IFN
Antiviral + IFN + CDCA
0%
20%
40%
60%
80%
100%
120%
Mock 17AAG 0.5 17AAG 0.2
Antiviral
Antiviral + IFN
Antiviral + IFN + CDCA
0%
20%
40%
60%
80%
100%
120%
Mock Cyclo 1 Cyclo 0.5
Antiviral
Antiviral + IFN
Antiviral + IFN + CDCA
 
 138
Figure 4-3. Western Blot Analysis of Antiviral Compounds in Combination with IFN-α and 
CDCA. 
Semi-confluent GS4.1 cells were incubated with mock-medium, CDCA, CDCA + IFN, Ribavirin 
or Cyclosporine or 17-AAG, or a combination of CDCA + IFN + either Ribavirin, Cyclosporine, 
or 17-AAG for 24 hours. A) Western blot analysis of GS4.1 cells treated with mock-medium 
(Lane 1), CDCA 100 µM (Lane 2), Ribavirin 80 µM (Lane 3), Ribavirin and IFN 5 U/ml (Lane 
4), IFN and CDCA (Lane 5), and CDCA + IFN + Ribavirin (Lane 6). B) Western blot analysis of 
GS4.1 cells treated with mock-medium (Lane 1), CDCA 100 µM  (Lane 2), 17-AAG 0.5 µM 
(Lane 3), 17-AAG and IFN 5 U/ml (Lane 4), IFN and CDCA (Lane 5), and CDCA + IFN + 17-
AAG (Lane 6). C) Western blot analysis of GS4.1 cells treated with mock-medium (Lane 1), 
CDCA 100 µM  (Lane 2), Cyclosporine 1 µM (Lane 3), Cyclosporine and IFN 5 U/ml (Lane 4), 
IFN and CDCA (Lane 5), and CDCA + IFN + Cyclosporine (Lane 6). 
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 CHAPTER 5 - Conclusion and Future Directions 
Positive sense RNA viruses comprise a diverse group of human and animal viruses.  Their 
pathogenicity can range from sub-clinical to lethal and the rapid evolution of this group of 
viruses can rapidly create resistant mutants against our current stocks of antivirals.  There are 
currently a number of human and animal diseases caused by RNA viruses that no efficacious 
vaccine exists for.  A better understanding about the interactions between these viruses and their 
hosts cells will help to design better and more effective treatments to combat these viruses. 
 
The ability of various RNA viruses to disrupt and control a variety of host cellular pathways and 
cycles has been well documented.  The modulation of various host factors have been shown to 
alter the overall replication levels of viruses.  The research presented in this dissertation 
specifically looks at the modulation of the cell surface receptor CD163 and the role it plays in the 
replication of the PRRSV virus, the effects of bile acids on the replication of HCV and how the 
disruption of the EGFR and the ERK pathway mitigates this enhancement in replication of HCV 
in the presence of bile acids.  Finally we studied the ability of bile acids to reduce the overall 
effectiveness of 3 different known antiviral compounds to HCV. 
 
We first confirmed Calvert et al. initial findings suggesting that CD163 is able to create a 
PRRSV permissive cell line with the creation of the LLCPK-163 stable cell lines.  Following this 
we demonstrated that the expression of CD163 on the cell surface of PAMs, monocyte derived 
macrophages, and differentiating monocytes can be altered in the presence of TPA, LPS, and IL-
10.  TPA significantly reduced the overall levels of CD163 expression on all three cell types.  A 
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decrease in the overall levels of CD163 after LPS treatment was only observed on the monocyte 
derived macrophages and differentiating monocytes.  An enhancement in the total levels of 
CD163 was seen after treatment of both monocyte derived macrophages and differentiating 
monocytes after IL-10 treatments.  All cells were infected with 129-GFP and the correlation 
between CD163 levels and PRRSV replication levels were observed.  There was a strong 
correlation between the expression level of CD163 and overall PRRSV levels, as determined by 
flow cytometry and TCID50.   Finally we showed that a monoclonal antibody to CD163 is 
sufficient to reduce the overall levels of PRRSV infection in PAMs. 
 
The second group of experiments focused on the effects of bile acids on the replication of HCV.  
Our lab group had previously demonstrated that bile acids could enhance the expression levels of 
HCV RNA and Proteins in GS4.1 replicon-harboring cells and that this enhancement interfered 
with the antiviral action of IFN-α.  We extended these results by demonstrating that this 
enhancement was due to the activation of the ERK pathway and by disrupting the activation of 
the ERK pathway by bile acids using either AG1478 or U0126 we could partially restore the 
antiviral activities of IFN-α.  We further showed that the addition of bile acids to both GS4.1 and 
1A7 cells alters the cell cycle profile and the extended S phase that is seen correlates with the 
increased levels of HCV RNA and proteins. 
 
The final group of experiments furthers the original HCV work looking at the effects of bile 
acids on the effectiveness of three known HCV antivirals.  In each of the three cases we 
demonstrated that the effectiveness of each antiviral was diminished in the presence of bile acids 
when used as a monotherapy alone.  When the antiviral was combined with IFN-α and enhanced 
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antiviral effect was seen in the presence of bile acids.  We demonstrated that in vitro the current 
therapy of Ribavirin and IFN-α was actually the least effective of the three combination 
treatments, and required far higher doses of Ribavirin than were required of cyclosporine A or 
17-AAG. 
 
The development of antivirals targeting specific host factors may prove beneficial in combating 
these different RNA viruses.  Further research on the bile acid mediated promotion of HCV 
replication will be necessary to elicit the overall impact on the current and future treatment 
regimes.  A more detailed study using a genotype 1 tissue culture adapted virus will help us to 
better understand how the activation of the ERK pathway by bile acids and HCV replication are 
tied together.  Using this information it may be possible to generate a series of treatments that 
block this promotion and enhance the overall effectiveness of the current HCV treatment 
protocols. 
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